

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	336	venom near4 (protease\$1 or metalloproteinase\$1 or metalloprotease\$1)	US-PGPUB; USPAT	OR	OFF	2004/06/16 10:04
L2	1993	cobra	US-PGPUB; USPAT	OR	OFF	2004/06/16 10:04
L3	22	1 same 2	US-PGPUB; USPAT	OR	OFF	2004/06/16 10:05
L4	1265	psgl or (p adj selectin)	US-PGPUB; USPAT	OR	OFF	2004/06/16 10:05
L5	118	(protease\$1 or metalloproteinase\$1 or metalloprotease\$1) same 4	US-PGPUB; USPAT	OR	OFF	2004/06/16 10:05
L6	14	1 and 5	US-PGPUB; USPAT	OR	OFF	2004/06/16 10:06
L7	9	mocarhagin	US-PGPUB; USPAT	OR	OFF	2004/06/16 10:06
(L8)	34	3 or 6 or 7	US-PGPUB; USPAT	OR	OFF	2004/06/16 10:06

2/18/98

PGPUB-DOCUMENT-NUMBER: 20040087539

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040087539 A1

TITLE: Method of treating conditions related to platelet activity

PUBLICATION-DATE: May 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Du, Xiaoping	Westmont	IL	US	

APPL-NO: 10/ 467387

DATE FILED: December 12, 2003

PCT-DATA:

APPL-NO: PCT/US02/03372

DATE-FILED: Feb 5, 2002

PUB-NO:

PUB-DATE:

371-DATE:

102(E)-DATE:

US-CL-CURRENT: 514/45, 514/263.3

ABSTRACT:

Methods of treating thrombotic and hemostatic conditions related to platelet activity are described herein. The methods of treating thrombotic and hemostatic conditions use active agents that modulate production of guanosine 3', 5' cyclic monophosphate (cGMP) or the function of cGMP-dependent protein kinase (PKG), and its downstream effectors, the ERK and p38 pathways.

CROSS REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 60/267,326, filed Feb. 8, 2001.

----- KWIC -----

Detail Description Paragraph - DETX (147):

[0168] 17. Ward C M, Andrews R K, Smith A L, Berndt M C: Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha-thrombin. Biochemistry 35:4929-4938, 1996

PGPUB-DOCUMENT-NUMBER: 20040002450

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040002450 A1

TITLE: Y17 - isolated molecules comprising epitopes containing
sulfated moieties, antibodies to such epitopes, and uses
thereof

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lazarovits, Janette	Reut		IL	
Hagay, Yocheved	Rehovot		IL	
Plaksin, Daniel	Rehovot		IL	
Vogel, Tikva	Rehovot		IL	
Nimrod, Abraham	Rehovot		IL	
Mar-Ham, Hagit	Aseret		IL	
Szanthon, Ester	Rehovot		IL	
Richter, Tamar	Nes Tziona		IL	
Amit, Boaz	Kiron	IL		
Cooperman, Lena	Rishon Lezion		IL	
Peretz, Tuvia	Hod Hasharon		IL	
Levanon, Avigdor	Rehovot		IL	

APPL-NO: 10/ 032423

DATE FILED: December 31, 2001

RELATED-US-APPL-DATA:

non-provisional-of-provisional 60258948 20001229 US

US-CL-CURRENT: 514/12, 514/13 , 514/14 , 514/15 , 514/16 , 530/324 , 530/325
, 530/326 , 530/327 , 530/328

ABSTRACT:

The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compositions using antibodies capable of binding to the epitopes are provided. Methods and compositions according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application is a Continuation-in-Part application of U.S. provisional application Serial No. 60/258,948, filed on Dec. 29, 2000, the subject matter of which is incorporated by reference hereto.

----- KWIC -----

Brief Description of Drawings Paragraph - DRTX

(8):

[0187] FIG. 7 depicts a Western blot demonstrating that Y1 binds the N-terminal (His 1-Glu 282) fragment of platelet GPIb.alpha. after cleavage by mocarhagin.

Brief Description of Drawings Paragraph - DRTX

(9):

[0188] FIG. 8 depicts a Western blot showing binding of Y1 and Y17 to glyocalicin after cleavage by mocarhagin.

Brief Description of Drawings Paragraph - DRTX

(14):

[0193] FIG. 13 depicts a Western blot demonstrating that cleavage of glyocalicin by mocarhagin and cathepsin G abolishes binding of Y1.

Brief Description of Drawings Paragraph - DRTX

(15):

[0194] FIG. 14 depicts a Western blot showing the binding of Y1 and Y17 to lysate of washed platelets cleaved by mocarhagin and cathepsin G.

Detail Description Paragraph - DETX (7):

[0237] The human platelet derived glyocalicin extracellular fragment was purified from activated platelets. It was digested with various proteases, such as ficin, mocarhagin, cathepsin G, in order to localize precisely the Y1 binding epitope on the glyocalicin molecule. Analysis was performed by the Western blot methodology using the Y1 antibody as a detection tool. In addition, commercially available anti-glyocalicin antibodies (antibodies that are known to bind to different epitopes of glyocalicin) were used in a competition binding assay with the Y1 antibody to determine the Y1 binding epitope on glyocalicin.

Detail Description Paragraph - DETX (119):

[0349] Mocarhagin Cleavage of GPIb--Mapping of the Y1 Epitope

Detail Description Paragraph - DETX (120):

[0350] Mocarhagin [Sigma L4515a] is a cobra venom metalloproteinase that cleaves platelet GPIb.alpha. specifically at a single site between residues glu-282 and asp-283, thereby generating two stable products: a .about.45-kDa N-terminal fragment (His1-Glu282), which is released into the supernatant, and a membrane-bound .about.95 kDa C-terminal fragment.

Detail Description Paragraph - DETX (121):

[0351] Washed platelets were treated by mocarhagin, and platelet lysates were electrophoresed on SDS-polyacrylamide gels and transferred to nitrocellulose. Western blot analysis of lysates of mocarhagin-treated washed platelets with Y1 shows a loss of the band corresponding to GPIb.alpha. (135 kDa) and binding of Y1 to the N-terminal .about.45 kDa tryptic fragment. A monoclonal antibody (MCA466S) directed against the C-terminal fragment of GPIb.alpha. reacted with the .about.95 kDa C-terminal fragment, and a monoclonal antibody (S.C.7071) directed against the N-terminal fragment of GPIb.alpha. reacted with the same .about.45 kDa fragment that was recognized by Y1. (FIG. 7).

Detail Description Paragraph - DETX (122):

[0352] Mocarhagin treatment of glyocalicin (soluble, extracellular fragment of GPIb.alpha.) gave similar results to those observed with washed platelets, showing binding of Y1 and monoclonal antibody S.C.7071 to the .about.45 kDa N-terminal cleavage product fragment of GPIb.alpha.. (FIG. 8). These results suggest that the epitope for Y1 is contained within the sequence His1-Glu282.

Detail Description Paragraph - DETX (139):

[0369] These results further support the hypothesis that sulfated tyrosine residues within the specific region are important for Y1 recognition on GPIb. Overall, analysis of N-terminal peptide proteolytic fragments of mocarhagin and cathepsin G suggest that the GPIb.alpha. amino acid sequence Tyr276-Glu-282 is or contains an important epitope for binding of Y1. (FIGS. Tab 1C pages 6 and 7). Further characterization indicated that in addition to residues 276-282 (sulfated anionic sequence) of glyocalicin, upstream amino acids 283-285 are involved in the recognition site of Y1.

Detail Description Paragraph - DETX (332):

[0555] 3.1 Cleavage of Platelets by Mocarhagin

Detail Description Paragraph - DETX (333):

[0556] For mocarhagin digestion, 10.sup.8 washed platelets in TS buffer (0.01 M Tris, 0.15 M sodium chloride, pH 7.4) containing 1 mM calcium chloride were treated with 12 .mu.g/ml mocarhagin (final concentration) for 1 hour at 22.degree. C. and digestion was stopped by adding EDTA to 0.01 M.

Detail Description Paragraph - DETX (340):

[0561] Cleavage of Glycocalicin by Mocarhagin

Detail Description Paragraph - DETX (341):

[0562] For mocarhagin digestion, glycocalicin in TS buffer containing 1 mM calcium chloride was incubated with 10 .mu.g/ml mocarhagin (final concentration) for 1 hour at 22.degree. C. and digestion was stopped by adding EDTA to 0.01 M.

Detail Description Paragraph - DETX (475):

[0668] 18.1: Effect of Mocarhagin on the Mapping of Y1 Epitope

Detail Description Paragraph - DETX (476):

[0669] Mocarhagin, a cobra venom metalloproteinase cleaves platelet GPIb.alpha. specifically at a single site between residues glu-282 and asp-283, generates two stable products, a 45-kDa N-terminal fragment (His-1-Glu-282) found in the supernatant and a membrane bound 100 kDa C-terminal fragment.

Detail Description Paragraph - DETX (477):

[0670] Washed platelets were treated by mocarhagin and, platelets lysate were separated on SDS-polyacrylamide gels and transferred to nitrocellulose. Analysis of mocarhagin-treated washed platelets by Western blot analysis with Y1-results in loss of the band corresponding to GPb (135 kDa) and, binding of Y17 to the N-terminal 45 kDa tryptic fragment. Monoclonal antibodies, MCA466S directed against the C-terminal fragment of GPIb.alpha. reacted with the 100 kDa C-terminal fragment while, monoclonal antibody S.C.7071 which recognizes the N-terminal of GPIb.alpha. reacted with the same 45 kDa N-terminal fragment that was recognized by Y17 (FIG. 14).

Detail Description Paragraph - DETX (478):

[0671] Mocarhagin treatment of glycocalicin gave results similar to those observed with washed platelets, showing binding of Y1 and monoclonal antibodies, S.C. 7071 to 45 kDa N-terminal cleavage product fragment of GPIb.alpha. (FIG. 8). The results suggest that the epitope for Y17 is contained within the sequence His-1-Glu-282.

Detail Description Paragraph - DETX (480):

[0673] Cathepsin G, a neutrophil serine protease, cleaved glycocalicin

between residues leu-275 and Tyr-276 and a second cleavage site between residues Val-296 and Lys-297. Glycocalicin treated by cathepsin G generated two N-terminal fragments, a small fragment 42 kDa fragment (His1-Leu275) and a large 45 kDa N-terminal fragment (His1-Val-296), in addition to a .about.95 kDa C-terminal fragment. Glycocalicin and glycocalicin fragments generated by cathepsin G digestion were separated on SDS-polyacrylamide gels and transferred to nitrocellulose. Y17 bound to the larger fragment (His1-Val-296), but not to the smaller fragment (His1-Leu275). Moreover, monoclonal antibody S.C. 7071 which recognizes an epitope within His1-Leu275 blotted both fragments (FIG. 12). Analysis of N-terminal peptide proteolytic fragments of mocarhagin and cathepsin G suggests that the GPIb.alpha. amino acid sequence Tyr-276-Glu-282 is an important recognition motif for binding of Y17.

Detail Description Paragraph - DETX (483):

[0674] The effect of Y17-scFv on vWF-dependent agglutination of platelets was tested at different concentrations of Y17. In contrast to Y1, Y17 at a final concentration of 10, 25 or 50 .mu.g/ml did not inhibit vWF-dependent platelet agglutination in washed platelets induced by ristocetin. Analysis of N-terminal peptide proteolytic fragments of mocarhagin and cathepsin G suggests that the GPIb.alpha. amino acid sequence Tyr-276-Glu-282 is an important recognition motif for binding of Y17 and Y1. Since Y17 does not inhibit platelet aggregation, it seems that Y1 and Y17 do not bind to the same sequences, but to overlapping sequences.

Detail Description Table CWU - DETL (11):

11TABLE 10 Western Blot Analysis with Y1 on SDS-PAGE Reducing Gels Presented Reactivity in Substrate Treatment Condition with Y1 FIG. RP-HPLC KG- O-Sialo 30' at 37.degree. C. Reactivity Tab 2A 1 membrane glycoprotein only with slide 14 fraction endopep- the tidase 120 kDa form RP-HPLC KG- O-Sialo 4 hr at 37.degree. C. No Tab 2A 1 membrane glycoprotein reactivity slide 14 fraction endopep- tidase RP-HPLC KG- aryl-sulfatase 18 hr at 22.degree. C. No Tab 2A 1 membrane reactivity slide 14 fraction RP-HPLC KG- mocarhagin 7' at 37.degree. C. No Tab 2A 1 membrane reactivity slide 14 fraction Glycocalicin O-Sialo 30' at 37.degree. C. Enhanced Tab 2A (GC) glycoprotein binding slide 14 endopep- tidase Heparin - BSA aryl-sulfatase 18 hr at 22.degree. C. Binds to Tab 2A Y1 as slide 16 without treatment

PGPUB-DOCUMENT-NUMBER: 20040001839

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040001839 A1

TITLE: Multimers - isolated molecules comprising epitopes
containing sulfated moieties, antibodies to such
epitopes, and uses thereof

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Levanon, Avigdor	Rehovot		IL	
Hagay, Yocheved	Rehovot		IL	
Plaksin, Daniel	Rehovot		IL	
Vogel, Tikva	Rehovot		IL	
Nimrod, Abraham	Rehovot		IL	
Mar-Haim, Hagit	Aseret		IL	
Szanthon, Ester	Rehovot		IL	
Richter, Tamar	Nes Tziona		IL	
Amit, Boaz	Kiron	IL		
Cooperman, Lena	Rishon Lezion		IL	
Peretz, Tuvia	Hod Hasharon		IL	
Lazarovits, Janette	Reut		IL	

APPL-NO: 10/ 029988

DATE FILED: December 31, 2001

RELATED-US-APPL-DATA:

non-provisional-of-provisional 60258948 20001229 US

US-CL-CURRENT: 424/178.1, 530/391.1

ABSTRACT:

The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compositions using antibodies capable of binding to the epitopes are provided. Methods and compositions according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease

FIELD OF THE INVENTION

[0001] This application is a Continuation-in-Part application of U.S. provisional application Serial No. 60/258,948, filed on Dec. 29, 2000, the subject matter of which is incorporated by reference hereto.

----- KWIC -----

Brief Description of Drawings Paragraph - DRTX
(8):

[0160] FIG. 7 depicts a Western blot demonstrating that Y1 binds the N-terminal (His1-Glu282) fragment of platelet GPIb.alpha. after cleavage by mocarhagin.

Brief Description of Drawings Paragraph - DRTX

(9):

[0161] FIG. 8 depicts a Western blot showing binding of Y1 and Y17 to glycosialicin after cleavage by mocarhagin.

Brief Description of Drawings Paragraph - DRTX

(14):

[0166] FIG. 13 depicts a Western blot demonstrating that cleavage of glycosialicin by mocarhagin and cathepsin G abolishes binding of Y1.

Brief Description of Drawings Paragraph - DRTX

(15):

[0167] FIG. 14 depicts a Western blot showing the binding of Y1 and Y17 to lysate of washed platelets cleaved by mocarhagin and cathepsin G.

Detail Description Paragraph - DETX (7):

[0210] The human platelet derived glycosialicin extracellular fragment was purified from activated platelets. It was digested with various proteases, such as ficin, mocarhagin, cathepsin G, in order to localize precisely the Y1 binding epitope on the glycosialicin molecule. Analysis was performed by the Western blot methodology using the Y1 antibody as a detection tool. In addition, commercially available anti-glycosialicin antibodies (antibodies that are known to bind to different epitopes of glycosialicin) were used in a competition binding assay with the Y1 antibody to determine the Y1 binding epitope on glycosialicin.

Detail Description Paragraph - DETX (119):

[0322] Mocarhagin Cleavage of GPIb--Mapping of the Y1 Epitope

Detail Description Paragraph - DETX (120):

[0323] Mocarhagin [Sigma L4515a] is a cobra venom metalloproteinase that cleaves platelet GPIb.alpha. specifically at a single site between residues glu-282 and asp-283, thereby generating two stable products: a .about.45-kDa N-terminal fragment (His1-Glu282), which is released into the supernatant, and a membrane-bound .about.95 kDa C-terminal fragment.

Detail Description Paragraph - DETX (121):

[0324] Washed platelets were treated by mocarhagin, and platelet lysates were electrophoresed on SDS-polyacrylamide gels and transferred to nitrocellulose. Western blot analysis of lysates of mocarhagin-treated washed platelets with Y1 shows a loss of the band corresponding to GPIb.alpha. (135 kDa) and binding of Y1 to the N-terminal .about.45 kDa tryptic fragment. A monoclonal antibody (MCA466S) directed against the C-terminal fragment of GPIba reacted with the .about.95 kDa C-terminal fragment, and a monoclonal antibody (S.C.7071) directed against the N-terminal fragment of GPIb.alpha. reacted with the same .about.45 kDa fragment that was recognized by Y1. (FIG. 7).

Detail Description Paragraph - DETX (122):

[0325] Mocarhagin treatment of glycosialicin (soluble, extracellular fragment of GPIb.alpha.) gave similar results to those observed with washed platelets, showing binding of Y1 and monoclonal antibody S.C.7071 to the .about.45 kDa N-terminal cleavage product fragment of GPIb.alpha.. (FIG. 8). These results suggest that the epitope for Y1 is contained within the sequence His1-Glu282.

Detail Description Paragraph - DETX (139):

[0342] These results further support the hypothesis that sulfated tyrosine residues within the specific region are important for Y1 recognition on GPIb. Overall, analysis of N-terminal peptide proteolytic fragments of mocarhagin and cathepsin G suggest that the GPIb.alpha. amino acid sequence Tyr276-Glu-282 is or contains an important epitope for binding of Y1. (FIGS. Tab 1C pages 6 and 7). Further characterization indicated that in addition to residues 276-282 (sulfated anionic sequence) of glyocalicin, upstream amino acids 283-285 are involved in the recognition site of Y 1.

Detail Description Paragraph - DETX (333):

[0529] 3.1 Cleavage of Platelets by Mocarhagin

Detail Description Paragraph - DETX (334):

[0530] For mocarhagin digestion, 10.sup.8 washed platelets in TS buffer (0.01 M Tris, 0.15 M sodium chloride, pH 7.4) containing 1 mM calcium chloride were treated with 12 .mu.g/ml mocarhagin (final concentration) for 1 hour at 22.degree. C. and digestion was stopped by adding EDTA to 0.01 M.

Detail Description Paragraph - DETX (341):

[0535] Cleavage of Glycocalicin by Mocarhagin

Detail Description Paragraph - DETX (342):

[0536] For mocarhagin digestion, glyocalicin in TS buffer containing 1 mM calcium chloride was incubated with 10 .mu.g/ml mocarhagin (final concentration) for 1 hour at 22.degree. C. and digestion was stopped by adding EDTA to 0.01 M.

Detail Description Paragraph - DETX (483):

[0649] 18.1: Effect of Mocarhagin on the Mapping of Y1 Epitope

Detail Description Paragraph - DETX (484):

[0650] Mocarhagin, a cobra venom metalloproteinase cleaves platelet GPIb.alpha. specifically at a single site between residues glu-282 and asp-283, generates two stable products, a 45-kDa N-terminal fragment (His-1-Glu-282) found in the supernatant and a membrane bound 100 kDa C-terminal fragment.

Detail Description Paragraph - DETX (485):

[0651] Washed platelets were treated by mocarhagin and, platelets lysate were separated on SDS-polyacrylamide gels and transferred to nitrocellulose. Analysis of mocarhagin-treated washed platelets by Western blot analysis with Y1-results in loss of the band corresponding to GPIb (135 kDa) and, binding of Y17 to the N-terminal 45 kDa tryptic fragment. Monoclonal antibodies, MCA466S directed against the C-terminal fragment of GPIb.alpha. reacted with the 100 kDa C-terminal fragment while, monoclonal antibody S.C.7071 which recognizes the N-terminal of GPIb.alpha. reacted with the same 45 kDa N-terminal fragment that was recognized by Y17 (FIG. 14).

Detail Description Paragraph - DETX (486):

[0652] Mocarhagin treatment of glyocalicin gave results similar to those observed with washed platelets, showing binding of Y1 and monoclonal antibodies, S.C. 7071 to 45 kDa N-terminal cleavage product fragment of GPIb.alpha. (FIG. 8). The results suggest that the epitope for Y17 is contained within the sequence His-1-Glu-282.

Detail Description Paragraph - DETX (488):

[0654] Cathepsin G, a neutrophil serine protease, cleaved glyocalicin between residues leu-275 and Tyr-276 and a second cleavage site between residues Val-296 and Lys-297. Glycocalicin treated by cathepsin G generated

two N-terminal fragments, a small fragment 42 kDa fragment (His1-Leu275) and a large 45 kDa N-terminal fragment (His1-Val-296), in addition to a .about.95 kDa C-terminal fragment. Glycocalicin and glycocalicin fragments generated by cathepsin G digestion were separated on SDS-polyacrylamide gels and transferred to nitrocellulose. Y17 bound to the larger fragment (His1-Val-296), but not to the smaller fragment (His1-Leu275). Moreover, monoclonal antibody S.C. 7071 which recognizes an epitope within His1-Leu275 blotted both fragments (FIG. 12). Analysis of N-terminal peptide proteolytic fragments of mocarhagin and cathepsin G suggests that the GPIb.alpha. amino acid sequence Tyr-276-Glu-282 is an important recognition motif for binding of Y17.

Detail Description Paragraph - DETX (491):

[0655] The effect of Y17-scFv on vWF-dependent agglutination of platelets was tested at different concentrations of Y17. In contrast to Y1, Y17 at a final concentration of 10, 25 or 50 .mu.g/ml did not inhibit vWF-dependent platelet agglutination in washed platelets induced by ristocetin. Analysis of N-terminal peptide proteolytic fragments of mocarhagin and cathepsin G suggests that the GPIb.alpha. amino acid sequence Tyr-276-Glu-282 is an important recognition motif for binding of Y17 and Y1. Since Y17 does not inhibit platelet aggregation, it seems that Y1 and Y17 do not bind to the same sequences, but to overlapping sequences.

Detail Description Table CWU - DETL (11):

11TABLE 10 Western Blot Analysis with Y1 on SDS-PAGE Reducing Gels
 Reactivity Presented with in Substrate Treatment Condition Y1 FIG. RP-HPLC
 KG-1 O-Sialo 30' at Reactivity Tab 2A membrane glycoprotein 37.degree. C.
 only with slide 14 fraction endopeptidase the 120 kDa form RP-HPLC KG-1
 O-Sialo 4 hr at No Tab 2A membrane glycoprotein 37.degree. C. reactivity slide
 14 fraction endopeptidase RP-HPLC KG-1 aryl-sulfatase 18 hr at No Tab 2A
 membrane 22.degree. C. reactivity slide 14 fraction RP-HPLC KG-1 mocarhagin
 7' at No Tab 2A membrane 37.degree. C. reactivity slide 14 fraction
 Glycocalicin O-Sialo 30' at Enhanced Tab 2A (GC) glycoprotein 37.degree. C.
 binding slide 14 endopeptidase Heparin - BSA aryl-sulfatase 18 hr at Binds to
 Tab 2A 22.degree. C. Y1 as slide 16 without treatment

PGPUB-DOCUMENT-NUMBER: 20040001822

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040001822 A1

TITLE: Y1-isolated molecules comprising epitopes containing
sulfated moieties, antibodies to such epitopes, and uses
thereof

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Levanon, Avigdor	Rehovot		IL	
Hagay, Yocheved	Rehovot		IL	
Plaksin, Daniel	Rehovot		IL	
Vogel, Tikva	Rehovot		IL	
Nimrod, Abraham	Rehovot		IL	
Mar-Haim, Hagit	Aseret		IL	
Szanthon, Esther	Rehovot		IL	
Richter, Tamar	Nes Tziona		IL	
Amit, Boaz	Kiron	IL		
Cooperman, Lena	Rishon Lezion		IL	
Peretz, Tuvia	Hod Hasharon		IL	
Lazarovits, Janette	Reut		IL	

APPL-NO: 10/ 032037

DATE FILED: December 31, 2001

RELATED-US-APPL-DATA:

non-provisional-of-provisional 60258948 20001229 US

US-CL-CURRENT: 424/130.1, 424/450 , 424/85.4 , 514/183 , 514/323 , 514/575
, 514/59 , 514/8 , 530/359 , 530/388.1

ABSTRACT:

The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compositions using antibodies capable of binding to the epitopes are provided. Methods and compositions according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease.

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application is a Continuation-in-Part application of U.S. provisional application Serial No. 60/258,948, filed on Dec. 29, 2000, the subject matter of which is incorporated by reference hereto.

----- KWIC -----

Brief Description of Drawings Paragraph - DRTX

(8):

[0187] FIG. 7 depicts a Western blot demonstrating that Y1 binds the N-terminal (His 1-Glu 282) fragment of platelet GPIb.alpha. after cleavage by mocarhagin.

Brief Description of Drawings Paragraph - DRTX

(9):

[0188] FIG. 8 depicts a Western blot showing binding of Y1 and Y17 to glyocalicin after cleavage by mocarhagin.

Brief Description of Drawings Paragraph - DRTX

(14):

[0193] FIG. 13 depicts a Western blot demonstrating that cleavage of glyocalicin by mocarhagin and cathepsin G abolishes binding of Y1.

Brief Description of Drawings Paragraph - DRTX

(15):

[0194] FIG. 14 depicts a Western blot showing the binding of Y1 and Y17 to lysate of washed platelets cleaved by mocarhagin and cathepsin G.

Detail Description Paragraph - DETX (7):

[0237] The human platelet derived glyocalicin extracellular fragment was purified from activated platelets. It was digested with various proteases, such as ficin, mocarhagin, cathepsin G, in order to localize precisely the Y1 binding epitope on the glyocalicin molecule. Analysis was performed by the Western blot methodology using the Y1 antibody as a detection tool. In addition, commercially available anti-glyocalicin antibodies (antibodies that are known to bind to different epitopes of glyocalicin) were used in a competition binding assay with the Y1 antibody to determine the Y1 binding epitope on glyocalicin.

Detail Description Paragraph - DETX (119):

[0349] Mocarhagin Cleavage of GPIb--Mapping of the Y1 Epitope

Detail Description Paragraph - DETX (120):

[0350] Mocarhagin [Sigma L4515a] is a cobra venom metalloproteinase that cleaves platelet GPIb.alpha. specifically at a single site between residues glu-282 and asp-283, thereby generating two stable products: a .about.45-kDa N-terminal fragment (His1-Glu282), which is released into the supernatant, and a membrane-bound .about.95 kDa C-terminal fragment.

Detail Description Paragraph - DETX (121):

[0351] Washed platelets were treated by mocarhagin, and platelet lysates were electrophoresed on SDS-polyacrylamide gels and transferred to nitrocellulose. Western blot analysis of lysates of mocarhagin-treated washed platelets with Y1 shows a loss of the band corresponding to GPIb.alpha. (135 kDa) and binding of Y1 to the N-terminal .about.45 kDa tryptic fragment. A monoclonal antibody (MCA466S) directed against the C-terminal fragment of GPIb.alpha. reacted with the .about.95 kDa C-terminal fragment, and a monoclonal antibody (S.C.7071) directed against the N-terminal fragment of GPIb.alpha. reacted with the same .about.45 kDa fragment that was recognized by Y1. (FIG. 7).

Detail Description Paragraph - DETX (122):

[0352] Mocarhagin treatment of glyocalicin (soluble, extracellular fragment of GPIb.alpha.) gave similar results to those observed with washed platelets, showing binding of Y1 and monoclonal antibody S.C.7071 to the .about.45 kDa N-terminal cleavage product fragment of GPIb.alpha.. (FIG. 8). These results suggest that the epitope for Y1 is contained within the sequence His1-Glu282.

Detail Description Paragraph - DETX (139):

[0369] These results further support the hypothesis that sulfated tyrosine residues within the specific region are important for Y1 recognition on GPIb. Overall, analysis of N-terminal peptide proteolytic fragments of mocarhagin and cathepsin G suggest that the GPIb.alpha. amino acid sequence Tyr276-Glu-282 is or contains an important epitope for binding of Y1. (FIGS. Tab 1C pages 6 and 7). Further characterization indicated that in addition to residues 276-282 (sulfated anionic sequence) of glyocalicin, upstream amino acids 283-285 are involved in the recognition site of Y 1.

Detail Description Paragraph - DETX (334):

[0560] 3.1 Cleavage of Platelets by Mocarhagin

Detail Description Paragraph - DETX (335):

[0561] For mocarhagin digestion, 10.sup.8 washed platelets in TS buffer (0.01 M Tris, 0.15 M sodium chloride, pH 7.4) containing 1 mM calcium chloride were treated with 12 .mu.g/ml mocarhagin (final concentration) for 1 hour at 22.degree. C. and digestion was stopped by adding EDTA to 0.01 M.

Detail Description Paragraph - DETX (342):

[0567] Cleavage of Glycocalicin by Mocarhagin

Detail Description Paragraph - DETX (343):

[0568] For mocarhagin digestion, glycocalicin in TS buffer containing 1 mM calcium chloride was incubated with 10 .mu.g/ml mocarhagin (final concentration) for 1 hour at 22.degree. C. and digestion was stopped by adding EDTA to 0.01 M.

Detail Description Paragraph - DETX (473):

[0684] 18.1: Effect of Mocarhagin on the Mapping of Y1 Epitope

Detail Description Paragraph - DETX (474):

[0685] Mocarhagin, a cobra venom metalloproteinase cleaves platelet GPIb.alpha. specifically at a single site between residues glu-282 and asp-283, generates two stable products, a 45-kDa N-terminal fragment (His-1-Glu-282) found in the supernatant and a membrane bound 100 kDa C-terminal fragment.

Detail Description Paragraph - DETX (475):

[0686] Washed platelets were treated by mocarhagin and, platelets lysate were separated on SDS-polyacrylamide gels and transferred to nitrocellulose. Analysis of mocarhagin-treated washed platelets by Western blot analysis with Y1-results in loss of the band corresponding to GPIb (135 kDa) and, binding of Y17 to the N-terminal 45 kDa tryptic fragment. Monoclonal antibodies, MCA466S directed against the C-terminal fragment of GPIb.alpha. reacted with the 100 kDa C-terminal fragment while, monoclonal antibody S.C.7071 which recognizes the N-terminal of GPIb.alpha. reacted with the same 45 kDa N-terminal fragment that was recognized by Y17 (FIG. 14).

Detail Description Paragraph - DETX (476):

[0687] Mocarhagin treatment of glycocalicin gave results similar to those observed with washed platelets, showing binding of Y1 and monoclonal antibodies, S.C. 7071 to 45 kDa N-terminal cleavage product fragment of GPIb.alpha. (FIG. 8). The results suggest that the epitope for Y17 is contained within the sequence His-1-Glu-282.

Detail Description Paragraph - DETX (478):

[0689] Cathepsin G, a neutrophil serine protease, cleaved glycocalicin

between residues leu-275 and Tyr-276 and a second cleavage site between residues Val-296 and Lys-297. Glycocalicin treated by cathepsin G generated two N-terminal fragments, a small fragment 42 kDa fragment (His1-Leu275) and a large 45 kDa N-terminal fragment (His1-Val-296), in addition to a 95 kDa C-terminal fragment. Glycocalicin and glycocalicin fragments generated by cathepsin G digestion were separated on SDS-polyacrylamide gels and transferred to nitrocellulose. Y17 bound to the larger fragment (His1-Val-296), but not to the smaller fragment (His1-Leu275). Moreover, monoclonal antibody S.C. 7071 which recognizes an epitope within His1-Leu275 blotted both fragments (FIG. 12). Analysis of N-terminal peptide proteolytic fragments of mocarhagin and cathepsin G suggests that the GPIb.alpha. amino acid sequence Tyr-276-Glu-282 is an important recognition motif for binding of Y17.

Detail Description Paragraph - DETX (481):

[0691] The effect of Y17-scFv on vWF-dependent agglutination of platelets was tested at different concentrations of Y17. In contrast to Y1, Y17 at a final concentration of 10, 25 or 50 .mu.g/ml did not inhibit vWF-dependent platelet agglutination in washed platelets induced by ristocetin. Analysis of N-terminal peptide proteolytic fragments of mocarhagin and cathepsin G suggests that the GPIb.alpha. amino acid sequence Tyr-276-Glu-282 is an important recognition motif for binding of Y17 and Y1. Since Y17 does not inhibit platelet aggregation, it seems that Y1 and Y17 do not bind to the same sequences, but to overlapping sequences.

Detail Description Table CWU - DETL (11):

11TABLE 10 Presented Reactivity in Substrate Treatment Condition with Y1
 FIG. RP-HPLC KG- O-Sialo 30' at 37.degree. C. Reactivity Tab 2A 1 membrane glycoprotein only slide 14 fraction endopeptidase with the 120 kDa form
 RP-HPLC KG- O-Sialo 4 hr at 37.degree. C. No Tab 2A 1 membrane glycoprotein reactivity slide 14 fraction endopeptidase RP-HPLC KG- aryl-sulfatase 18 hr at 22.degree. C. No Tab 2A 1 membrane reactivity slide 14 fraction RP-HPLC KG- Mocarhagin 7' at 37.degree. C. No Tab 2A 1 membrane reactivity slide 14 fraction Glycocalicin O-Sialo 30' at 37.degree. C. Enhanced Tab 2A (GC) glycoprotein binding slide 14 endopeptidase Heparin - aryl-sulfatase 18 hr at 22.degree. C. Binds to Tab 2A BSA Y1 as slide 16 without treatment

PGPUB-DOCUMENT-NUMBER: 20030232753

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030232753 A1

TITLE: Combined tissue factor methods for coagulation and tumor treatment

PUBLICATION-DATE: December 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Thorpe, Philip E.	Dallas	TX	US	
King, Steven W.	Foothill Ranch	CA	US	
Gao, Boning	Dallas	TX	US	

APPL-NO: 10/ 375741

DATE FILED: February 27, 2003

RELATED-US-APPL-DATA:

child 10375741 A1 20030227

parent continuation-of 09573835 20000518 US PENDING

child 09573835 20000518 US

parent division-of 09009822 19980120 US GRANTED

parent-patent 6156321 US

non-provisional-of-provisional 60042427 19970327 US

non-provisional-of-provisional 60036205 19970127 US

non-provisional-of-provisional 60035920 19970122 US

US-CL-CURRENT: 514/12

ABSTRACT:

The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.

[0001] The present application is a non-provisional application directed to the subject matter of provisional application Serial No. 60/042,427 (Attorney

Docket No. UTSD:517PZ3), filed Mar. 27, 1997; provisional application Serial No. 60/036,205 (Attorney Docket No. UTSD:517PZ2), filed Jan. 27, 1997; and provisional application Serial No. 60/035,920 (Attorney Docket No. UTSD:517PZ1), filed Jan. 22, 1997; the entire disclosures of each of which provisional applications are incorporated herein by reference without disclaimer.

----- KWIC -----

Detail Description Paragraph - DETX (263):

[0351] Coagulants, such as thrombin, Factor IX/IXa, Factor X/Xa, plasmin and metalloproteinases, such as interstitial collagenases, stromelysins and gelatinases, also act to induce certain markers. In particular, E-selectin, P-selectin, PDGF and ICAM-1 are induced by thrombin (Sugama et. al., 1992; Shankar et. al., 1994).

Detail Description Paragraph - DETX (331):

[0419] Russell's viper venom was shown to contain a coagulant protein by Williams and Esnouf in 1962. Kisiel (1979) isolated a venom glycoprotein that activates Factor V; and Di Scipio et al. (1977) showed that a protease from the venom activates human Factor X. The Factor X activator is the component contemplated for use in this invention.

PGPUB-DOCUMENT-NUMBER: 20030219441

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030219441 A1

TITLE: Combined methods and compositions for coagulation and tumor treatment

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Thorpe, Philip E.	Dallas	TX	US	
Edgington, Thomas S.	La Jolla	CA	US	

APPL-NO: 10/ 375716

DATE FILED: February 27, 2003

RELATED-US-APPL-DATA:

child 10375716 A1 20030227

parent continuation-of 09483679 20000114 US PENDING

child 09483679 20000114 US

parent continuation-of 08482369 19950607 US GRANTED

parent-patent 6093399 US

child 08482369 19950607 US

parent continuation-in-part-of 08273567 19940711 US ABANDONED

child 08273567 19940711 US

parent continuation-in-part-of 08205330 19940302 US GRANTED

parent-patent 5855866 US

child 08205330 19940302 US

parent continuation-in-part-of 07846349 19920305 US ABANDONED

US-CL-CURRENT: 424/155.1, 530/388.8

ABSTRACT:

Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody.

[0001] The present application is a continuation-in-part of co-pending U.S.

patent application Ser. No. 08/273,567, filed Jun. 11, 1994; which is a continuation-in-part of co-pending U.S. patent application Ser. No. 08/205,330, filed, Mar. 2, 1994; which is a continuation-in-part of U.S. Ser. No. 07/846,349, filed Mar. 5, 1992. The entire text and figures of the above-referenced disclosures are specifically incorporated herein by reference without disclaimer.

----- KWIC -----

Summary of Invention Paragraph - BSTX (44):

[0043] Further inducible antigens include those inducible by a coagulant, such as by thrombin, Factor IX/IXa, Factor X/Xa, plasmin or a metalloproteinase (matrix metalloproteinase, MMP). Generally, antigens inducible by thrombin will be used. This group of antigens includes P-selectin, E-selectin, PDGF and ICAM-1, with the induction and targeting of P-selectin and/or E-selectin being generally preferred.

Detail Description Paragraph - DETX (77):

[0179] Coagulants, such as thrombin, Factor IX/IXa, Factor X/Xa, plasmin and metalloproteinases, such as interstitial collagenases, stromelysins and gelatinases, also act to induce certain markers. In particular, E-selectin, P-selectin, PDGF and ICAM-1 are induced by thrombin (Sugama et. al., 1992; Shankar et. al., 1994).

Detail Description Paragraph - DETX (144):

[0246] Russell's viper venom was shown to contain a coagulant protein by Williams and Esnouf in 1962. Kisiel (1979) isolated a venom glycoprotein that activates Factor V; and Di Scipio et al. (1977) showed that a protease from the venom activates human Factor X. The Factor X activator is the component contemplated for use in this invention.

PGPUB-DOCUMENT-NUMBER: 20030166194

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030166194 A1

TITLE: DNA clone of human tissue factor inhibitor

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wun, Tze Chein	Ballwin	MO	US	
Kretzmer, Kuniko K.	Wildwood	MO	US	
Broze, George J. JR.	St. Louis	MO	US	

APPL-NO: 10/ 377817

DATE FILED: March 4, 2003

RELATED-US-APPL-DATA:

child 10377817 A1 20030304

parent continuation-of 09627676 20000728 US GRANTED

parent-patent 6534276 US

child 09627676 20000728 US

parent continuation-of 09054782 19980403 US GRANTED

parent-patent 6171587 US

child 09054782 19980403 US

parent continuation-of 08463323 19950605 US GRANTED

parent-patent 5849875 US

child 08463323 19950605 US

parent continuation-of 08355351 19941213 US ABANDONED

child 08355351 19941213 US

parent continuation-of 08093285 19930715 US GRANTED

parent-patent 5466783 US

child 08093285 19930715 US

parent continuation-of 07566280 19900813 US ABANDONED

child 07566280 19900813 US

parent division-of 07123753 19871123 US GRANTED

parent-patent 4966852 US

child 07123753 19871123 US

parent continuation-in-part-of 07077366 19870723 US ABANDONED

US-CL-CURRENT: 435/184, 536/23.2

ABSTRACT:

A cDNA clone having a base sequence for human tissue factor inhibitor (TFI) has been developed and characterized and the amino acid sequence of the TFI has been determined.

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This is a continuation-in-part of copending application Ser. No. 77,366, filed Jul. 23, 1987.

----- KWIC -----

Brief Description of Drawings Paragraph - DRTX
(8):

[0021] FIG. 6 shows an alignment of the basic protease inhibitor domains of TFI with other basic protease inhibitors. All the sequences except TFI were obtained from the National Biomedical Research Foundation Protein Sequence Database (Georgetown University, Washington, D.C., release 13, June 1987). 1. Bovine basic protease inhibitor precursor; 2. Bovine colostrum trypsin inhibitor; 3. Bovine serum basic protease inhibitor; 4. Edible snail isoinhibitor K; 5. Red sea turtle basic protease inhibitor (only amino acids 1-79 presented); 6. Western sand viper venom basic protease inhibitor I; 7. Ringhals venom basic protease inhibitor II; 8. Cape cobra venom basic protease inhibitor II; 9. Russell's viper venom basic protease inhibitor II; 10. Sand viper venom basic protease inhibitor III; 11. Eastern green mamba venom basic protease inhibitor I homolog; 12. Black mamba venom basic protease inhibitor B; 13. Black mamba venom basic protease inhibitor E; 14. Black mamba venom basic protease inhibitor I; 15. Black mamba venom basic protease inhibitor K; 16. .beta.-1-Bungarotoxin B chain (minor); 17. .beta.-1-Bungarotoxin B chain (major); 18. .beta.-2-Bungarotoxin B chain; 19. Horse inter-.alpha.-trypsin inhibitor [amino acids 1-57(1); 58-123(2)]; 20. Pig inter-.alpha.-trypsin inhibitor [amino acids 1-57(1); 58-123(2)]; 21. Bovine inter-.alpha.-trypsin inhibitor [amino acids 1-57(1); 58-123(2)]; 22. Human .alpha.-1-microglobulin/inter-.alpha.-trypsin inhibitor precursor [amino acids 227-283(1); 284-352(2)]; 23. TFI [amino acids 47-117(1); 118-188(2); 210-280(3)]. Gaps were included in 16, 17, 18 to achieve best alignment. Standard one letter codes for amino acids are used.

US-PAT-NO: 6749853

DOCUMENT-IDENTIFIER: US 6749853 B1

TITLE: Combined methods and compositions for coagulation and tumor treatment

DATE-ISSUED: June 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Cape Elizabeth	ME	N/A	N/A
Edgington; Thomas S.	La Jolla	CA	N/A	N/A

APPL-NO: 09/ 483679

DATE FILED: January 14, 2000

PARENT-CASE:

The present application is a continuation of application Ser. No. 08/482,369, filed Jun. 7, 1995 (now issued as U.S. Pat. No. 6,093,399); which is a continuation-in-part of U.S. patent application Ser. No. 08/273,567, filed Jul. 11, 1994 now abandoned; which is a continuation-in-part of U.S. patent application Ser. No. 08/205,330, filed Mar. 2, 1994; (now issued as U.S. Pat. No. 5,855,866) which is a continuation-in-part of U.S. Ser. No. 07/846,349, filed Mar. 5, 1992 now abandoned. The entire text and figures of the above-referenced disclosures are specifically incorporated herein by reference without disclaimer.

US-CL-CURRENT: 424/182.1, 424/178.1, 530/387.1, 530/387.3

ABSTRACT:

Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody.

47 Claims, 11 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

----- KWIC -----

Brief Summary Text - BSTX (44):

Further inducible antigens include those inducible by a coagulant, such as by thrombin, Factor IX/IXa, Factor X/Xa, plasmin or a metalloproteinase (matrix metalloproteinase, MMP). Generally, antigens inducible by thrombin will be used. This group of antigens includes P-selectin, E-selectin, PDGF and ICAM-1, with the induction and targeting of P-selectin and/or E-selectin being generally preferred.

Detailed Description Text - DETX (76):

Coagulants, such as thrombin, Factor IX/IXa, Factor X/Xa, plasmin and metalloproteinases, such as interstitial collagenases, stromelysins and gelatinases, also act to induce certain markers. In particular, E-selectin, P-selectin, PDGF and ICAM-1 are induced by thrombin (Sugama et. al., 1992; Shankar et. al., 1994).

Detailed Description Text - DETX (142):

Russell's viper venom was shown to contain a coagulant protein by Williams and Esnouf in 1962. Kisiel (1979) isolated a venom glycoprotein that activates Factor V; and Di Scipio et al. (1977) showed that a protease from the venom activates human Factor X. The Factor X activator is the component contemplated for use in this invention.

US-PAT-NO: 6607897

DOCUMENT-IDENTIFIER: US 6607897 B2

TITLE: Recombinant proCVF

DATE-ISSUED: August 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vogel; Carl-Wilhelm	Hamburg	N/A	N/A	DE
Bredehorst; Reinhard	Hamburg	N/A	N/A	DE
Fritzinger; David	Alexandria	VA	N/A	N/A
Kock; Michael	Hamburg	N/A	N/A	DE

APPL-NO: 09/ 925442

DATE FILED: August 10, 2001

PARENT-CASE:

The present application is a Divisional application of Ser. No. 09/017,947 filed Feb. 3, 1998, U.S. Pat. No. 6,303,754 which is a Divisional application of Ser. No. 08/662,227 filed Jun. 14, 1996, U.S. Pat. No. 5,922,320.

US-CL-CURRENT: 435/69.1, 424/94.64, 435/226, 435/252.3, 435/320.1, 435/325, 514/12, 514/8, 530/380, 530/395, 536/23.2, 536/23.5

ABSTRACT:

Recombinant proCVF exhibits substantially the same activity as CVF and is useful for lowering complement activity.

20 Claims, 38 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 32

----- KWIC -----

Detailed Description Text - DETX (40):

Recently, protease activities have been characterized in cobra venom that are able to cleave human C3 into a form that resembles C3b functionally, but has a similar subunit structure to CVF1 (O'Keefe, M. C., et al, 1988, J. Biol. Chem. 263:12690). Since this activity appears to be specific, and not just a random protease, it is possible that this protease serves in the maturation pathway of CVF1. Comparing the venom protease cleavage sites in human C3 to the processing sites in CVF1 shows that the enzyme cleaves human C3 at a position 11 amino acid residues downstream from the actual CVF1 processing site at the N-terminus of the .gamma.-chain, though the venom protease site appears to be in the middle of one of the proposed Factor B binding sites. The second venom protease cleavage site is in a position similar to the C-terminus of the .gamma.-chain, though this position has not been mapped in CVF1. The third

venom protease cleavage site is in position 71 amino acids downstream from the N-terminus of the .beta.-chain.

Detailed Description Text - DETX (48):

Further, proCVF may be processed from the pre-pro-form by treatment with either whole cobra venom or the purified proteases from cobra venom, as described in the Doctoral thesis of M. Clare O'Keefe, Georgetown University, 1991. Thus, active proCVF may be obtained even when produced by a host incapable of the proper post-translational processing. Of course, in some expression systems proCVF will be secreted by the host even though the DNA encodes pre-proCVF.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:33:04 ON 16 JUN 2004

=> fil .bec

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILES 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS,
ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 10:33:16 ON 16 JUN 2004
ALL COPYRIGHTS AND RESTRICTIONS APPLY. SEE HELP USAGETERMS FOR DETAILS.

11 FILES IN THE FILE LIST

=> s protease# or metalloprote?

FILE 'MEDLINE'

73950 PROTEASE#

21144 METALLOPROTE?

L1 91625 PROTEASE# OR METALLOPROTE?

FILE 'SCISEARCH'

68863 PROTEASE#

22741 METALLOPROTE?

L2 88567 PROTEASE# OR METALLOPROTE?

FILE 'LIFESCI'

25265 PROTEASE#

4083 METALLOPROTE?

L3 28515 PROTEASE# OR METALLOPROTE?

FILE 'BIOTECHDS'

16273 PROTEASE#

440 METALLOPROTE?

L4 16408 PROTEASE# OR METALLOPROTE?

FILE 'BIOSIS'

81697 PROTEASE#

23998 METALLOPROTE?

L5 103095 PROTEASE# OR METALLOPROTE?

FILE 'EMBASE'

52743 PROTEASE#

19128 METALLOPROTE?

L6 69633 PROTEASE# OR METALLOPROTE?

FILE 'HCAPLUS'

95435 PROTEASE#

22001 METALLOPROTE?

L7 114249 PROTEASE# OR METALLOPROTE?

FILE 'NTIS'

602 PROTEASE#

215 METALLOPROTE?

L8 780 PROTEASE# OR METALLOPROTE?

FILE 'ESBIOBASE'

33414 PROTEASE#

10387 METALLOPROTE?

L9 41634 PROTEASE# OR METALLOPROTE?

FILE 'BIOTECHNO'

26983 PROTEASE#

9088 METALLOPROTE?

```

L10      34820 PROTEASE# OR METALLOPROTE?

FILE 'WPIDS'
      14289 PROTEASE#
      2014 METALLOPROTE?
L11      15882 PROTEASE# OR METALLOPROTE?

TOTAL FOR ALL FILES
L12      605208 PROTEASE# OR METALLOPROTE?

=> s cobra and venom(5a)l12
FILE 'MEDLINE'
      3231 COBRA
      14015 VENOM
      405 VENOM(5A)L1
L13      17 COBRA AND VENOM(5A)L1

FILE 'SCISEARCH'
      2172 COBRA
      14362 VENOM
      420 VENOM(5A)L2
L14      30 COBRA AND VENOM(5A)L2

FILE 'LIFESCI'
      774 COBRA
      6394 VENOM
      194 VENOM(5A)L3
L15      7 COBRA AND VENOM(5A)L3

FILE 'BIOTECHDS'
      55 COBRA
      445 VENOM
      19 VENOM(5A)L4
L16      1 COBRA AND VENOM(5A)L4

FILE 'BIOSIS'
      3406 COBRA
      19362 VENOM
      517 VENOM(5A)L5
L17      33 COBRA AND VENOM(5A)L5

FILE 'EMBASE'
      2139 COBRA
      17059 VENOM
      382 VENOM(5A)L6
L18      16 COBRA AND VENOM(5A)L6

FILE 'HCAPLUS'
      3808 COBRA
      20417 VENOM
      662 VENOM(5A)L7
L19      34 COBRA AND VENOM(5A)L7

FILE 'NTIS'
      604 COBRA
      295 VENOM
      6 VENOM(5A)L8
L20      0 COBRA AND VENOM(5A)L8

FILE 'ESBIOBASE'
      546 COBRA
      4263 VENOM
      234 VENOM(5A)L9
L21      12 COBRA AND VENOM(5A)L9

```

```

FILE 'BIOTECHNO'
    606 COBRA
    4053 VENOM
    182 VENOM(5A)L10
L22      6 COBRA AND VENOM(5A)L10

FILE 'WPIDS'
    137 COBRA
    943 VENOM
    23 VENOM(5A)L11
L23      3 COBRA AND VENOM(5A)L11

TOTAL FOR ALL FILES
L24      159 COBRA AND VENOM(5A) L12

=> s naja and venom(5a)l12
FILE 'MEDLINE'
    1333 NAJA
    14015 VENOM
    405 VENOM(5A)L1
L25      10 NAJA AND VENOM(5A)L1

FILE 'SCISEARCH'
    1225 NAJA
    14362 VENOM
    420 VENOM(5A)L2
L26      13 NAJA AND VENOM(5A)L2

FILE 'LIFESCI'
    625 NAJA
    6394 VENOM
    194 VENOM(5A)L3
L27      4 NAJA AND VENOM(5A)L3

FILE 'BIOTECHDS'
    25 NAJA
    445 VENOM
    19 VENOM(5A)L4
L28      1 NAJA AND VENOM(5A)L4

FILE 'BIOSIS'
    2729 NAJA
    19362 VENOM
    517 VENOM(5A)L5
L29      15 NAJA AND VENOM(5A)L5

FILE 'EMBASE'
    1119 NAJA
    17059 VENOM
    382 VENOM(5A)L6
L30      9 NAJA AND VENOM(5A)L6

FILE 'HCAPLUS'
    2855 NAJA
    20417 VENOM
    662 VENOM(5A)L7
L31      32 NAJA AND VENOM(5A)L7

FILE 'NTIS'
    44 NAJA
    295 VENOM
    6 VENOM(5A)L8
L32      0 NAJA AND VENOM(5A)L8

```

```

FILE 'ESBIOBASE'
    338 NAJA
    4263 VENOM
    234 VENOM(5A)L9
L33      9 NAJA AND VENOM(5A)L9

FILE 'BIOTECHNO'
    318 NAJA
    4053 VENOM
    182 VENOM(5A)L10
L34      6 NAJA AND VENOM(5A)L10

FILE 'WPIDS'
    35 NAJA
    943 VENOM
    23 VENOM(5A)L11
L35      2 NAJA AND VENOM(5A)L11

TOTAL FOR ALL FILES
L36      101 NAJA AND VENOM(5A) L12

=> s psgl or p(w)selectin
FILE 'MEDLINE'
    270 PSGL
    2287455 P
    9446 SELECTIN
    3825 P(W)SELECTIN
L37      3837 PSGL OR P(W)SELECTIN

FILE 'SCISEARCH'
    387 PSGL
    1074323 P
    12514 SELECTIN
    5531 P(W)SELECTIN
L38      5574 PSGL OR P(W)SELECTIN

FILE 'LIFESCI'
    93 PSGL
    198006 P
    2009 SELECTIN
    566 P(W)SELECTIN
L39      575 PSGL OR P(W)SELECTIN

FILE 'BIOTECHDS'
    13 PSGL
    28120 P
    208 SELECTIN
    69 P(W)SELECTIN
L40      71 PSGL OR P(W)SELECTIN

FILE 'BIOSIS'
    391 PSGL
    1082457 P
    11084 SELECTIN
    4672 P(W)SELECTIN
L41      4712 PSGL OR P(W)SELECTIN

FILE 'EMBASE'
    259 PSGL
    888949 P
    8535 SELECTIN
    2965 P(W)SELECTIN
L42      2979 PSGL OR P(W)SELECTIN

```

```

FILE 'HCAPLUS'
    428 PSGL
    2218557 P
    8007 SELECTIN
    3130 P(W) SELECTIN
L43    3146 PSGL OR P(W) SELECTIN

FILE 'NTIS'
    0 PSGL
    58420 P
    14 SELECTIN
    5 P(W) SELECTIN
L44    5 PSGL OR P(W) SELECTIN

FILE 'ESBIOBASE'
    221 PSGL
    345639 P
    5033 SELECTIN
    1964 P(W) SELECTIN
L45    1984 PSGL OR P(W) SELECTIN

FILE 'BIOTECHNO'
    139 PSGL
    187964 P
    3297 SELECTIN
    1014 P(W) SELECTIN
L46    1023 PSGL OR P(W) SELECTIN

FILE 'WPIDS'
    28 PSGL
    334406 P
    507 SELECTIN
    173 P(W) SELECTIN
L47    176 PSGL OR P(W) SELECTIN

TOTAL FOR ALL FILES
L48    24082 PSGL OR P(W) SELECTIN

=> s l48 and l12
FILE 'MEDLINE'
L49    91 L37 AND L1

FILE 'SCISEARCH'
L50    121 L38 AND L2

FILE 'LIFESCI'
L51    15 L39 AND L3

FILE 'BIOTECHDS'
L52    9 L40 AND L4

FILE 'BIOSIS'
L53    91 L41 AND L5

FILE 'EMBASE'
L54    59 L42 AND L6

FILE 'HCAPLUS'
L55    78 L43 AND L7

FILE 'NTIS'
L56    0 L44 AND L8

```

FILE 'ESBIOBASE'
L57 38 L45 AND L9

FILE 'BIOTECHNO'
L58 29 L46 AND L10

FILE 'WPIDS'
L59 20 L47 AND L11

TOTAL FOR ALL FILES
L60 551 L48 AND L12

=> s mocarhagin
FILE 'MEDLINE'
L61 20 MOCARHAGIN

FILE 'SCISEARCH'
L62 19 MOCARHAGIN

FILE 'LIFESCI'
L63 5 MOCARHAGIN

FILE 'BIOTECHDS'
L64 1 MOCARHAGIN

FILE 'BIOSIS'
L65 24 MOCARHAGIN

FILE 'EMBASE'
L66 17 MOCARHAGIN

FILE 'HCAPLUS'
L67 23 MOCARHAGIN

FILE 'NTIS'
L68 0 MOCARHAGIN

FILE 'ESBIOBASE'
L69 14 MOCARHAGIN

FILE 'BIOTECHNO'
L70 9 MOCARHAGIN

FILE 'WPIDS'
L71 2 MOCARHAGIN

TOTAL FOR ALL FILES
L72 134 MOCARHAGIN

=> s (l24 or l36 or l60 or l72) not 1999-2004/py
FILE 'MEDLINE'
2798713 1999-2004/PY
L73 49 (L13 OR L25 OR L49 OR L61) NOT 1999-2004/PY

FILE 'SCISEARCH'
5393010 1999-2004/PY
L74 47 (L14 OR L26 OR L50 OR L62) NOT 1999-2004/PY

FILE 'LIFESCI'
562403 1999-2004/PY
L75 13 (L15 OR L27 OR L51 OR L63) NOT 1999-2004/PY

FILE 'BIOTECHDS'
101830 1999-2004/PY

L76 3 (L16 OR L28 OR L52 OR L64) NOT 1999-2004/PY

FILE 'BIOSIS'

2938645 1999-2004/PY

L77 59 (L17 OR L29 OR L53 OR L65) NOT 1999-2004/PY

FILE 'EMBASE'

2460677 1999-2004/PY

L78 36 (L18 OR L30 OR L54 OR L66) NOT 1999-2004/PY

FILE 'HCAPLUS'

5166091 1999-2004/PY

L79 53 (L19 OR L31 OR L55 OR L67) NOT 1999-2004/PY

FILE 'NTIS'

94742 1999-2004/PY

L80 0 (L20 OR L32 OR L56 OR L68) NOT 1999-2004/PY

FILE 'ESBIOBASE'

1563021 1999-2004/PY

L81 18 (L21 OR L33 OR L57 OR L69) NOT 1999-2004/PY

FILE 'BIOTECHNO'

611346 1999-2004/PY

L82 19 (L22 OR L34 OR L58 OR L70) NOT 1999-2004/PY

FILE 'WPIDS'

4591795 1999-2004/PY

L83 0 (L23 OR L35 OR L59 OR L71) NOT 1999-2004/PY

TOTAL FOR ALL FILES

L84 297 (L24 OR L36 OR L60 OR L72) NOT 1999-2004/PY

=> dup rem l84

PROCESSING COMPLETED FOR L84

L85 120 DUP REM L84 (177 DUPLICATES REMOVED)

=> d tot

L85 ANSWER 1 OF 120 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN

TI Isolated **mocarhagin cobra venom**

protease, and nucleic acids encoding it;

Mozambiquan spitting **cobra venom** recombinant

metallo **protease** preparation by vector-mediated gene

transfer and expression in host cell, used for inflammatory disease

therapy

AU Boodhoo A; Seehra J S; Shaw G; Sako D

AN 1999-00528 BIOTECHDS

PI WO 9846771 22 Oct 1998

L85 ANSWER 2 OF 120 MEDLINE on STN

TI A balance of opposing signals within the cytoplasmic tail controls the lysosomal targeting of **P-selectin**.

SO Journal of biological chemistry, (1998 Oct 23) 273 (43) 27896-903.

Journal code: 2985121R. ISSN: 0021-9258.

AU Blagoveshchenskaya A D; Hewitt E W; Cutler D F

AN 1998447632 MEDLINE

L85 ANSWER 3 OF 120 LIFESCI COPYRIGHT 2004 CSA on STN

TI Modulation of Lipopolysaccharide-Induced Monocyte Activation by Heparin-Binding Protein and Fucoidan

SO Infection and Immunity, (19981200) vol. 66, no. 12, pp. 5842-5847.

ISSN: 0019-9567.

AU Heinzelmann, M.; Polk, H.C., Jr.; Miller, F.N.

AN 1999:29079 LIFESCI

L85 ANSWER 4 OF 120 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 TI Expression of hirudin fusion proteins in mammalian cells: a strategy for prevention of intravascular thrombosis; recombinant hirudin, CD4, **P-selectin** fusion protein expression in host cell, used in thrombosis gene therapy
 SO Circulation; (1998) 98, 24, 2744-52
 CODEN: CIRCAZ ISSN: 0009-7322
 AU Riesbeck K; Chen D; Kemball-Cook G; McVey J H; George A J T; Tuddenham E G D; Dorling A; *Lechler R I
 AN 1999-05489 BIOTECHDS

L85 ANSWER 5 OF 120 MEDLINE on STN DUPLICATE 1
 TI Effects of a **metalloproteinase** that truncates **P-selectin** glycoprotein ligand on neutrophil-induced cardiac dysfunction in ischemia/reperfusion.
 SO Journal of molecular and cellular cardiology, (1998 Dec) 30 (12) 2561-6.
 Journal code: 0262322. ISSN: 0022-2828.
 AU Lefer A M; Campbell B; Shin Y K
 AN 1999144339 MEDLINE

L85 ANSWER 6 OF 120 MEDLINE on STN
 TI Quinine-dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex: characterization of the epitopes.
 SO Blood, (1998 Oct 1) 92 (7) 2366-73.
 Journal code: 7603509. ISSN: 0006-4971.
 AU Burgess J K; Lopez J A; Berndt M C; Dawes I; Chesterman C N; Chong B H
 AN 1998421381 MEDLINE

L85 ANSWER 7 OF 120 MEDLINE on STN
 TI Effects of 0.2 ppm ozone on biomarkers of inflammation in bronchoalveolar lavage fluid and bronchial mucosa of healthy subjects.
 SO European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology, (1998 Jun) 11 (6) 1294-300.
 Journal code: 8803460. ISSN: 0903-1936.
 AU Krishna M T; Madden J; Teran L M; Biscione G L; Lau L C; Withers N J; Sandstrom T; Mudway I; Kelly F J; Walls A; Frew A J; Holgate S T
 AN 1998319674 MEDLINE

L85 ANSWER 8 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 TI Isolation and partial amino acid sequence of a novel **metalloprotease** from the **venom** of the colubrid snake *Hydrodynastes gigas* (false water **cobra**).
 SO Toxicon, (Sept., 1998) Vol. 36, No. 9, pp. 1250. print.
 Meeting Info.: 12th World Congress on Animal, Plant and Microbial Toxins. Cuernavaca, Mexico, USA. September 21-26, 1997.
 CODEN: TOXIA6. ISSN: 0041-0101.
 AU Mackessy, Stephen P. [Reprint author]
 AN 1998:460421 BIOSIS

L85 ANSWER 9 OF 120 MEDLINE on STN DUPLICATE 2
 TI Aprotinin reduces the expression of **p-selectin** on the surface of platelet and leukocyte-platelet conjugates.
 SO Artificial organs, (1998 Dec) 22 (12) 1018-22.
 Journal code: 7802778. ISSN: 0160-564X.
 AU Inui K; Shimazaki Y; Watanabe T; Kuraoka S; Uesho K; Uchida T; Shiono S
 AN 1999091321 MEDLINE

L85 ANSWER 10 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
 TI The composition of **Naja naja** venom samples from three districts of West Bengal, India
 SO Comparative Biochemistry and Physiology, Part A: Molecular & Integrative Physiology (1998), 119A(2), 621-627

CODEN: CBPAB5; ISSN: 0300-9629

AU Mukherjee, A. K.; Maity, C. R.

AN 1998:94023 HCAPLUS

DN 128:189384

L85 ANSWER 11 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI Evaluation of the anticoagulant effects of a highly specific snake venom metalloproteinase.

SO Blood, (Nov. 15, 1998) Vol. 92, No. 10 SUPPL. 1 PART 1-2, pp. 552A. print.
Meeting Info.: 40th Annual Meeting of the American Society of Hematology.
Miami Beach, Florida, USA. December 4-8, 1998. The American Society of Hematology.

CODEN: BLOOAW. ISSN: 0006-4971.

AU Kumar, A.; Patel, H.; Rajewski, J.; Parmar, P.; Bond, M.; Shaw, G.; Sako, D.; Keith, J. C., Jr.; Schaub, R. G.

AN 1999:120062 BIOSIS

L85 ANSWER 12 OF 120 MEDLINE on STN DUPLICATE 3

TI Purification and characterization of kaouthiagin, a von Willebrand factor-binding and -cleaving **metalloproteinase** from Naja kaouthia **cobra venom**.

SO Thrombosis and haemostasis, (1998 Sep) 80 (3) 499-505.
Journal code: 7608063. ISSN: 0340-6245.

AU Hamako J; Matsui T; Nishida S; Nomura S; Fujimura Y; Ito M; Ozeki Y; Titani K

AN 1998430434 MEDLINE

L85 ANSWER 13 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI cDNA cloning and expression of cobrin, the C3-cleaving **metalloprotease** from **Cobra venom**.

SO Molecular Immunology, (April-May, 1998) Vol. 35, No. 6-7, pp. 408. print.
Meeting Info.: XVII International Complement Workshop. Rhodes, Greece.
October 11-16, 1998.

CODEN: MOIMD5. ISSN: 0161-5890.

AU Bambai, Bijam; Teppke, Manfred; Bredehorst, Reinhard; Vogel, Carl-Wilhelm

AN 1998:521936 BIOSIS

L85 ANSWER 14 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI The molecular and cellular biology of pancreatic cancer.

SO Critical Reviews in Eukaryotic Gene Expression, (1998) Vol. 8, No. 3-4, pp. 377-393. print.

CODEN: CRGEEJ. ISSN: 1045-4403.

AU Perugini, Richard A.; McDade, Theodore P.; Vittimberga, Frank J., Jr.; Callery, Mark P. [Reprint author]

AN 1999:17392 BIOSIS

L85 ANSWER 15 OF 120 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN

TI cDNA cloning and expression of cobrin, the C3-cleaving **metalloprotease** from **cobra venom**

SO MOLECULAR IMMUNOLOGY, (APR-MAY 1998) Vol. 35, No. 6-7, Sp. iss. SI, pp. 311-311.

Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND.

ISSN: 0161-5890.

AU Bambai B (Reprint); Teppke M; Bredehorst R; Vogel C W

AN 1998:745708 SCISEARCH

L85 ANSWER 16 OF 120 MEDLINE on STN DUPLICATE 4

TI Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection.

SO FASEB journal : official publication of the Federation of American Societies for Experimental Biology, (1998 Jan) 12 (1) 79-89.

Journal code: 8804484. ISSN: 0892-6638.

AU Holme P A; Muller F; Solum N O; Brosstad F; Froland S S; Aukrust P

AN 1998099250 MEDLINE

L85 ANSWER 17 OF 120 MEDLINE on STN DUPLICATE 5

TI The neutrophil and preeclampsia.

SO Seminars in reproductive endocrinology, (1998) 16 (1) 57-64. Ref: 98
Journal code: 8308354. ISSN: 0734-8630.

AU Clark P; Boswell F; Greer I A

AN 1998318677 MEDLINE

L85 ANSWER 18 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

TI **Mocarhagin, a cobra venom protease**

, and therapeutic uses thereof.

SO Official Gazette of the United States Patent and Trademark Office Patents,
(Aug. 19, 1997) Vol. 1201, No. 3, pp. 2175. print.
CODEN: OGUPE7. ISSN: 0098-1133.

AU Berndt, M. C. [Inventor]; Dunlop, L. [Inventor]; Andrews, R. [Inventor];
Deluca, M. [Inventor]

AN 2002:82166 BIOSIS

L85 ANSWER 19 OF 120 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN

TI Factor Xa as an interface between coagulation and inflammation - Molecular
mimicry of factor Xa association with effector cell **protease**
receptor-1 induces acute inflammation in vivo

SO JOURNAL OF CLINICAL INVESTIGATION, (15 MAY 1997) Vol. 99, No. 10, pp.
2446-2451.

Publisher: ROCKEFELLER UNIV PRESS, 1114 FIRST AVE, 4TH FL, NEW YORK, NY
10021.

ISSN: 0021-9738.

AU Cirino G; Cicala C; Bucci M; Sorrentino L; Ambrosini G; DeDominicis G;
Altieri D C (Reprint)

AN 97:425451 SCISEARCH

L85 ANSWER 20 OF 120 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN

TI Kaouthiagin, a **metalloproteinase** purified from **Naja**
kaouthia **cobra venom**, specifically binds to and
cleaves von Willebrand factor.

SO BLOOD, (15 NOV 1997) Vol. 90, No. 10, Part 1, Supp. [1], pp. 2071-2071.

Publisher: W B SAUNDERS CO, INDEPENDENCE SQUARE WEST CURTIS CENTER, STE
300, PHILADELPHIA, PA 19106-3399.

ISSN: 0006-4971.

AU Matsui T (Reprint); Hamako J; Fujimura Y; Nishida S; Ito M; Ozeki Y;
Titani K; Takamatsu J

AN 97:879006 SCISEARCH

L85 ANSWER 21 OF 120 MEDLINE on STN DUPLICATE 6

TI A tissue plasminogen activator/**P-selectin** fusion
protein is an effective thrombolytic agent.

SO Circulation, (1997 Feb 4) 95 (3) 715-22.

Journal code: 0147763. ISSN: 0009-7322.

AU Fujise K; Revelle B M; Stacy L; Madison E L; Yeh E T; Willerson J T; Beck
P J

AN 97176623 MEDLINE

L85 ANSWER 22 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

TI Kaouthiagin, a **metalloproteinase** purified from **Naja**
kaouthia **cobra venom**, specifically binds to and
cleaves von Willebrand factor.

SO Blood, (Nov. 15, 1997) Vol. 90, No. 10 SUPPL. 1 PART 1, pp. 466A. print.
Meeting Info.: 39th Annual Meeting of the American Society of Hematology.
San Diego, California, USA. December 5-9, 1997. The American Society of
Hematology.

CODEN: BLOOAW. ISSN: 0006-4971.

AU Matsui, T.; Hamako, J.; Fujimura, Y.; Nishida, S.; Ito, M.; Ozeki, Y.;
Titani, K.; Takamatsu, J.

AN 1998:68380 BIOSIS

L85 ANSWER 23 OF 120 MEDLINE on STN
 TI Postangioplasty restenosis: platelet activation and the
 coagulation-fibrinolysis system as possible factors in the pathogenesis of
 restenosis.
 SO American heart journal, (1997 Apr) 133 (4) 387-92.
 Journal code: 0370465. ISSN: 0002-8703.
 AU Ishiwata S; Tukada T; Nakanishi S; Nishiyama S; Seki A
 AN 97240357 MEDLINE

L85 ANSWER 24 OF 120 MEDLINE on STN DUPLICATE 7
 TI Thrombosis and atherosclerosis.
 SO Current opinion in lipidology, (1997 Oct) 8 (5) 320-8. Ref: 89
 Journal code: 9010000. ISSN: 0957-9672.
 AU Holvoet P; Collen D
 AN 97476673 MEDLINE

L85 ANSWER 25 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 TI Tetanus toxin inhibits activation-dependent **P-selectin**
 surface expression in permeabilized platelets.
 SO Blood, (Nov. 15, 1997) Vol. 90, No. 10 SUPPL. 1 PART 1, pp. 282A. print.
 Meeting Info.: 39th Annual Meeting of the American Society of Hematology.
 San Diego, California, USA. December 5-9, 1997. The American Society of
 Hematology.
 CODEN: BLOOAW. ISSN: 0006-4971.
 AU Flaumenhaft, R. [Reprint author]; Croce, K.; Furie, B. C.; Furie, B.
 AN 1998:67550 BIOSIS

L85 ANSWER 26 OF 120 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
 TI Endothelial cell injury in cardiovascular surgery: The systemic
 inflammatory response
 SO ANNALS OF THORACIC SURGERY, (JAN 1997) Vol. 63, No. 1, pp. 277-284.
 Publisher: ELSEVIER SCIENCE INC, 655 AVENUE OF THE AMERICAS, NEW YORK, NY
 10010.
 ISSN: 0003-4975.
 AU Boyle E M; Pohlman T H; Johnson M C; Verrier E D (Reprint)
 AN 97:71167 SCISEARCH

L85 ANSWER 27 OF 120 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
 TI The role of the endothelium in inflammation and tumor metastasis
 SO INTERNATIONAL JOURNAL OF MICROCIRCULATION-CLINICAL AND EXPERIMENTAL, (OCT
 1997) Vol. 17, No. 5, pp. 257-272.
 Publisher: KARGER, ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND.
 ISSN: 0167-6865.
 AU Siegel G (Reprint); Malmsten M
 AN 97:827869 SCISEARCH

L85 ANSWER 28 OF 120 LIFESCI COPYRIGHT 2004 CSA on STN
 TI Role of macrophages in vascular tissue remodelling
 SO TRANSPLANT IMMUNOL., (19970000) vol. 5, no. 3, pp. 173-176.
 ISSN: 0966-3274.
 AU Wahl, L.M.; Shankavaram, U.; Zhang, Yahong
 AN 1998:29437 LIFESCI

L85 ANSWER 29 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 TI Preoperative platelet dysfunction increases the benefit of aprotinin in
 cardiopulmonary bypass.
 SO Annals of Thoracic Surgery, (1997) Vol. 63, No. 1, pp. 57-63.
 ISSN: 0003-4975.
 AU Ray, Michael J.; Marsh, Neville A.; Just, Sarah J. E.; Perrin, Emma J.;
 O'Brien, Mark F.; Hawson, Geoffrey A. T.
 AN 1997:106848 BIOSIS

L85 ANSWER 30 OF 120 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
 TI The systemic inflammatory response
 SO ANNALS OF THORACIC SURGERY, (OCT 1997) Vol. 64, No. 4, Supp. [S], pp. S31-S37.
 Publisher: ELSEVIER SCIENCE INC, 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010.
 ISSN: 0003-4975.
 AU Boyle E M; Pohlman T H; Johnson M C; Verrier E D (Reprint)
 AN 97:801914 SCISEARCH

L85 ANSWER 31 OF 120 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
 TI Cytokines, growth factors and renal injury: Where do we go now?
 SO KIDNEY INTERNATIONAL, (DEC 1997) Supp. [63], pp. S2-S6.
 Publisher: BLACKWELL SCIENCE INC, 350 MAIN ST, MALDEN, MA 02148.
 ISSN: 0085-2538.
 AU Johnson R J (Reprint)
 AN 97:905416 SCISEARCH

L85 ANSWER 32 OF 120 MEDLINE on STN DUPLICATE 8
 TI **Mocarhagin**, a novel **cobra venom metalloproteinase**, cleaves the platelet von Willebrand factor receptor glycoprotein Ib α . Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ib α as a binding site for von Willebrand factor and α -thrombin.
 SO Biochemistry, (1996 Apr 16) 35 (15) 4929-38.
 Journal code: 0370623. ISSN: 0006-2960.
 AU Ward C M; Andrews R K; Smith A I; Berndt M C
 AN 96267086 MEDLINE

L85 ANSWER 33 OF 120 MEDLINE on STN DUPLICATE 9
 TI Generation of a new gamma delta T cell-specific monoclonal antibody (GD3.5). Biochemical comparisons of GD3.5 antigen with the previously described Workshop Cluster 1 (WC1) family.
 SO Journal of immunology (Baltimore, Md. : 1950), (1996 May 15) 156 (10) 3772-9.
 Journal code: 2985117R. ISSN: 0022-1767.
 AU Jones W M; Walcheck B; Jutila M A
 AN 96204468 MEDLINE

L85 ANSWER 34 OF 120 MEDLINE on STN DUPLICATE 10
 TI Effects of E-selectin and **P-selectin** blockade on neutrophil sequestration in tissues and neutrophil oxidative burst in burned rats.
 SO Critical care medicine, (1996 Aug) 24 (8) 1366-72.
 Journal code: 0355501. ISSN: 0090-3493.
 AU Hansbrough J F; Wikstrom T; Braide M; Tenenhaus M; Rennekampff O H; Kiessig V; Zapata-Sirvent R; Bjursten L M
 AN 96322880 MEDLINE

L85 ANSWER 35 OF 120 MEDLINE on STN DUPLICATE 11
 TI Characterization of **mocarhagin**, a **cobra venom metalloproteinase** from **Naja mocambique mocambique**, and related proteins from other Elapidae venoms.
 SO Toxicon : official journal of the International Society on Toxinology, (1996 Oct) 34 (10) 1203-6.
 Journal code: 1307333. ISSN: 0041-0101.
 AU Ward C M; Vinogradov D V; Andrews R K; Berndt M C
 AN 97084940 MEDLINE

L85 ANSWER 36 OF 120 MEDLINE on STN DUPLICATE 12
 TI Interactions of human α /beta and gamma/delta T lymphocyte subsets in shear flow with E-selectin and **p-selectin**.
 SO Journal of experimental medicine, (1996 Mar 1) 183 (3) 1193-203.
 Journal code: 2985109R. ISSN: 0022-1007.

AU Diacovo T G; Roth S J; Morita C T; Rosat J P; Brenner M B; Springer T A
AN 96228340 MEDLINE

L85 ANSWER 37 OF 120 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
TI SIALYLATED, FUCOSYLATED LIGANDS FOR L-SELECTIN EXPRESSED ON LEUKOCYTES
MEDIATE TETHERING AND ROLLING ADHESIONS IN PHYSIOLOGICAL FLOW CONDITIONS
SO JOURNAL OF CELL BIOLOGY, (NOV 1996) Vol. 135, No. 3, pp. 837-848.
ISSN: 0021-9525.
AU FUHLBRIGGE R C; ALON R; PURI K D; LOWE J B; SPRINGER T A (Reprint)
AN 96:819924 SCISEARCH

L85 ANSWER 38 OF 120 MEDLINE on STN
TI Neutrophil rolling altered by inhibition of L-selectin shedding in vitro.
SO Nature, (1996 Apr 25) 380 (6576) 720-3.
Journal code: 0410462. ISSN: 0028-0836.
AU Walcheck B; Kahn J; Fisher J M; Wang B B; Fisk R S; Payan D G; Feehan C;
Betageri R; Darlak K; Spatola A F; Kishimoto T K
AN 96202732 MEDLINE

L85 ANSWER 39 OF 120 MEDLINE on STN DUPLICATE 13
TI **P-selectin** glycoprotein ligand 1 is a ligand for
L-selectin on neutrophils, monocytes, and CD34+ hematopoietic progenitor
cells.
SO Journal of cell biology, (1996 Oct) 135 (2) 523-31.
Journal code: 0375356. ISSN: 0021-9525.
AU Spertini O; Cordey A S; Monai N; Giuffre L; Schapira M
AN 97051972 MEDLINE

L85 ANSWER 40 OF 120 MEDLINE on STN
TI Plasma **P selectin** (GMP-140) and glycocalicin are
elevated in preeclampsia and eclampsia: their significances.
SO American journal of obstetrics and gynecology, (1996 Jan) 174 (1 Pt 1)
272-7.
Journal code: 0370476. ISSN: 0002-9378.
AU Halim A; Kanayama N; el Maradny E; Nakashima A; Bhuiyan A B; Khatun S;
Terao T
AN 96148702 MEDLINE

L85 ANSWER 41 OF 120 MEDLINE on STN DUPLICATE 14
TI Flow cytometric evaluation of the effect of various thrombin inhibitors on
platelet activation in whole blood.
SO Thrombosis research, (1996 May 1) 82 (3) 257-63.
Journal code: 0326377. ISSN: 0049-3848.
AU Kaiser B; Koza M; Walenga J M; Fareed J
AN 96311055 MEDLINE

L85 ANSWER 42 OF 120 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
TI SUBSETS OF SIALYLATED, SULFATED MUCINS OF DIVERSE ORIGINS ARE RECOGNIZED
BY L-SELECTIN - LACK OF EVIDENCE FOR UNIQUE OLIGOSACCHARIDE SEQUENCES
MEDIATING BINDING
SO GLYCOBIOLOGY, (MAR 1996) Vol. 6, No. 2, pp. 191-208.
ISSN: 0959-6658.
AU CROTTET P; KIM Y J; VARKI A (Reprint)
AN 96:317513 SCISEARCH

L85 ANSWER 43 OF 120 MEDLINE on STN DUPLICATE 15
TI A novel **cobra venom metalloproteinase**,
mocarhagin, cleaves a 10-amino acid peptide from the mature N
terminus of **P-selectin** glycoprotein ligand receptor,
PSGL-1, and abolishes **P-selectin** binding.
SO Journal of biological chemistry, (1995 Nov 10) 270 (45) 26734-7.
Journal code: 2985121R. ISSN: 0021-9258.
AU De Luca M; Dunlop L C; Andrews R K; Flannery J V Jr; Ettling R; Cumming D
A; Veldman G M; Berndt M C

AN 96070754 MEDLINE

L85 ANSWER 44 OF 120 MEDLINE on STN DUPLICATE 16
 TI Primitive human hematopoietic progenitors adhere to **P-selectin** (CD62P).
 SO Blood, (1995 Jun 15) 85 (12) 3466-77.
 Journal code: 7603509. ISSN: 0006-4971.
 AU Zannettino A C; Berndt M C; Butcher C; Butcher E C; Vadas M A; Simmons P J
 AN 95299131 MEDLINE

L85 ANSWER 45 OF 120 MEDLINE on STN DUPLICATE 17
 TI Specific sensitivity of CD43 to neutrophil elastase.
 SO Blood, (1995 Sep 15) 86 (6) 2395-402.
 Journal code: 7603509. ISSN: 0006-4971.
 AU Remold-O'Donnell E; Parent D
 AN 95392000 MEDLINE

L85 ANSWER 46 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
 TI Functional analysis of **P-selectin** mAb of the selectin panel
 SO Leucocyte Typing V: White Cell Differentiation Antigens, Proceedings of the International Workshop and Conference, 5th, Boston, Nov. 3-7, 1993 (1995), Meeting Date 1993, Volume 2, 1512-1514. Editor(s): Schlossman, Stuart F. Publisher: Oxford University Press, Oxford, UK.
 CODEN: 63WDAC
 AU De Bruijne-Admiraal, Lucia G.; Von Dem Borne, Albert E. G. Km.
 AN 1997:47476 HCAPLUS
 DN 126:87602

L85 ANSWER 47 OF 120 MEDLINE on STN DUPLICATE 18
 TI Isolation and properties of a blood coagulation factor X activator from the venom of king **cobra** (*Ophiophagus hannah*).
 SO Toxicon : official journal of the International Society on Toxinology, (1995 Oct) 33 (10) 1263-76.
 Journal code: 1307333. ISSN: 0041-0101.
 AU Lee W H; Zhang Y; Wang W Y; Xiong Y L; Gao R
 AN 96151321 MEDLINE

L85 ANSWER 48 OF 120 MEDLINE on STN
 TI Cross-reactivity of human molecular markers for detection of prethrombotic states in various animal species.
 SO Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, (1995 Jul) 6 (5) 446-55.
 Journal code: 9102551. ISSN: 0957-5235.
 AU Ravanat C; Freund M; Dol F; Cadroy Y; Roussi J; Incardona F; Maffrand J P; Boneu B; Drouet L; Legrand C; +
 AN 96172773 MEDLINE

L85 ANSWER 49 OF 120 MEDLINE on STN DUPLICATE 19
 TI Influence of temperature on neutrophil trafficking during clinical cardiopulmonary bypass.
 SO Circulation, (1995 Nov 1) 92 (9 Suppl) II334-40.
 Journal code: 0147763. ISSN: 0009-7322.
 AU Menasche P; Peynet J; Haeffner-Cavaillon N; Carreno M P; de Chaumaray T; Dillisse V; Faris B; Piwnica A; Bloch G; Tedgui A
 AN 96069224 MEDLINE

L85 ANSWER 50 OF 120 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
 TI Influence of temperature on neutrophil trafficking during clinical cardiopulmonary bypass
 SO Circulation, (1995), 92/9 SUPPL. (II334-II340)
 CODEN: CIRCAZ ISSN: 0009-7322
 AU Menasche P.; Peynet J.; Haeffner-Cavaillon N.; Carreno M.-P.; De Chaumaray T.; Dillisse V.; Faris B.; Piwnica A.; Bloch G.; Tedgui A.

AN 1995:25341231 BIOTECHNO

L85 ANSWER 51 OF 120 MEDLINE on STN
 TI Platelet-activating factor produced by endothelial cells. A molecule with autocrine and paracrine properties.
 SO European journal of biochemistry / FEBS, (1995 Apr 15) 229 (2) 327-37.
 Ref: 115
 Journal code: 0107600. ISSN: 0014-2956.
 AU Bussolino F; Camussi G
 AN 95262695 MEDLINE

L85 ANSWER 52 OF 120 MEDLINE on STN DUPLICATE 20
 TI Comparison of human eosinophil and neutrophil ligands for **P-selectin**: ligands for **P-selectin** differ from those for E-selectin.
 SO American journal of respiratory cell and molecular biology, (1995 Mar) 12 (3) 315-9.
 Journal code: 8917225. ISSN: 1044-1549.
 AU Wein M; Sterbinsky S A; Bickel C A; Schleimer R P; Bochner B S
 AN 95178121 MEDLINE

L85 ANSWER 53 OF 120 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
 TI A NOVEL **COBRA VENOM METALLOPROTEINASE**, **MOCARHAGIN**, CLEAVES A 10-AMINO-ACID PEPTIDE FROM THE MATURE N-TERMINUS OF **P-SELECTIN** GLYCOPROTEIN LIGAND-RECEPTOR, **PSGL-1**, AND ABOLISHES **P-SELECTIN** BINDING
 SO BLOOD, (15 NOV 1995) Vol. 86, No. 10, Supp. 1, pp. 112.
 ISSN: 0006-4971.
 AU BERNDT M C (Reprint); DELUCA M; DUNLOP L C; ANDREWS R K; FLANNERY J V; ETTLING R; CUMMING D A; VELDMAN G M
 AN 96:16491 SCISEARCH

L85 ANSWER 54 OF 120 MEDLINE on STN DUPLICATE 21
 TI Mechanisms for lipoxin A4-induced neutrophil-dependent cytotoxicity for human endothelial cells.
 SO Journal of laboratory and clinical medicine, (1995 Jul) 126 (1) 36-43.
 Journal code: 0375375. ISSN: 0022-2143.
 AU Bratt J; Lerner R; Ringertz B; Palmblad J
 AN 95325755 MEDLINE

L85 ANSWER 55 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 TI A novel **cobra venom metalloproteinase**, **mocarhagin**, cleaves a ten amino acid peptide from the mature N-terminus of **P-selectin** glycoprotein ligand receptor, **PSGL-1**, and abolishes **P-selectin** binding.
 SO Blood, (1995) Vol. 86, No. 10 SUPPL. 1, pp. 31A.
 Meeting Info.: 37th Annual Meeting of the American Society of Hematology. Seattle, Washington, USA. December 1-5, 1995.
 CODEN: BLOOAW. ISSN: 0006-4971.
 AU Berndt, M. C. [Reprint author]; De Luca, M.; Dunlop, L. C.; Andrews, R. K.; Flannery., J. V., Jr.; Ettling, R.; Cumming, D. A.; Veldman, G. M.
 AN 1996:47807 BIOSIS

L85 ANSWER 56 OF 120 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 TI TPA-**P-selectin** fusion proteins in thrombolysis in vitro and in vivo;
 tissue plasminogen-activator-**P-selectin** fusion
 protein preparation by baculo virus vector-mediated gene expression in
 Spodoptera frugiperda cell culture (conference abstract)
 SO Circulation; (1995) 92, 8, Suppl., I-684
 CODEN: CIRCAZ ISSN: 0009-7322
 American Heart Association, 68th Scientific Sessions, Anaheim, CA, USA, 13-16 November, 1995.
 AU Fujise K; Scott D; Stacy L; Willerson J T; Beck P

AN 1996-03214 BIOTECHDS

L85 ANSWER 57 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI Snake **venom** hemorrhagic and non-hemorrhagic
metalloproteinases: Their structure and function relationships.
SO Katunuma, N. [Editor]; Suzuki, K. [Editor]; Travis, J. [Editor]; Fritz, H.
[Editor]. (1994) pp. 231-252. Biological functions of proteases and
inhibitors.
Publisher: Japan Scientific Societies Press, 2-10 Hongo, 6-chome,
Bunkyo-ku, Tokyo, Japan; S. Karger AG, P.O. Box, Allschwilerstrasse 10,
CH-4009 Basel, Switzerland.
ISBN: 3-8055-5954-2, 4-7622-7752-5.
AU Takeya, Hiroyuki; Iwanaga, Sadaaki
AN 1994:324223 BIOSIS

L85 ANSWER 58 OF 120 MEDLINE on STN DUPLICATE 22
TI Alternatively spliced isoform of **P-selectin** is present
in vivo as a soluble molecule.
SO Journal of biological chemistry, (1994 Sep 23) 269 (38) 23708-15.
Journal code: 2985121R. ISSN: 0021-9258.
AU Ishiwata N; Takio K; Katayama M; Watanabe K; Titani K; Ikeda Y; Handa M
AN 94375479 MEDLINE

L85 ANSWER 59 OF 120 MEDLINE on STN DUPLICATE 23
TI Functional properties of human factor Va lacking the Asp683-Arg709 domain
of the heavy chain.
SO Journal of biological chemistry, (1994 Aug 12) 269 (32) 20662-7.
Journal code: 2985121R. ISSN: 0021-9258.
AU Bakker H M; Tans G; Thomassen M C; Yukelson L Y; Ebberink R; Hemker H C;
Rosing J
AN 94327648 MEDLINE

L85 ANSWER 60 OF 120 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
TI CYTOKINE-ACTIVATED ENDOTHELIAL-CELLS INTERNALIZE E-SELECTIN INTO A
LYSOSOMAL COMPARTMENT OF VESICULOTUBULAR SHAPE - A TUBULIN-DRIVEN PROCESS
SO JOURNAL OF IMMUNOLOGY, (15 MAY 1994) Vol. 152, No. 10, pp. 5060-5069.
ISSN: 0022-1767.
AU KUIJPERS T W (Reprint); RALEIGH M; KAVANAGH T; JANSSEN H; CALAFAT J; ROOS
D; HARLAN J M
AN 94:281064 SCISEARCH

L85 ANSWER 61 OF 120 MEDLINE on STN DUPLICATE 24
TI Characterization of a spontaneously transformed human endothelial cell
line.
SO Laboratory investigation; a journal of technical methods and pathology,
(1994 Oct) 71 (4) 497-509.
Journal code: 0376617. ISSN: 0023-6837.
AU Cockerill G W; Meyer G; Noack L; Vadas M A; Gamble J R
AN 95057011 MEDLINE

L85 ANSWER 62 OF 120 MEDLINE on STN DUPLICATE 25
TI Human neutrophil cathepsin G is a potent platelet activator.
SO Journal of vascular surgery : official publication, Society for Vascular
Surgery [and] International Society for Cardiovascular Surgery, North
American Chapter, (1994 Feb) 19 (2) 306-18; discussion 318-9.
Journal code: 8407742. ISSN: 0741-5214.
AU LaRosa C A; Rohrer M J; Benoit S E; Rodino L J; Barnard M R; Michelson A D
AN 94158014 MEDLINE

L85 ANSWER 63 OF 120 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN DUPLICATE
26
TI PURIFICATION OF A NOVEL **COBRA VENOM PROTEASE**
THAT CLEAVES THE VON-WILLEBRAND-FACTOR RECEPTOR ON HUMAN PLATELETS AND THE
P-SELECTIN RECEPTOR ON NEUTROPHILS

SO JOURNAL OF CELLULAR BIOCHEMISTRY, (04 JAN 1994) Supp. 18A, pp. 294.
ISSN: 0730-2312.

AU ANDREWS R K (Reprint); WARD C M; DUNLOP L C; BERNDT M C
AN 94:96487 SCISEARCH

L85 ANSWER 64 OF 120 MEDLINE on STN
TI Shedding of adhesion receptors from the surface of activated platelets.
SO Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, (1994 Apr) 5 (2) 291-304. Ref: 98
Journal code: 9102551. ISSN: 0957-5235.

AU Fox J E
AN 94331538 MEDLINE

L85 ANSWER 65 OF 120 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
TI 3-DIMENSIONAL PROTEIN MODELS - INSIGHTS INTO STRUCTURE, FUNCTION, AND MOLECULAR-INTERACTIONS
SO BIOCONJUGATE CHEMISTRY, (MAY/JUN 1994) Vol. 5, No. 3, pp. 173-181.
ISSN: 1043-1802.

AU BAJORATH J (Reprint); ARUFFO A
AN 94:359235 SCISEARCH

L85 ANSWER 66 OF 120 MEDLINE on STN DUPLICATE 27
TI Neutrophil cathepsin G modulates the platelet surface expression of the glycoprotein (GP) Ib-IX complex by proteolysis of the von Willebrand factor binding site on GPIb alpha and by a cytoskeletal-mediated redistribution of the remainder of the complex.
SO Blood, (1994 Jul 1) 84 (1) 158-68.
Journal code: 7603509. ISSN: 0006-4971.

AU LaRosa C A; Rohrer M J; Benoit S E; Barnard M R; Michelson A D
AN 94289696 MEDLINE

L85 ANSWER 67 OF 120 MEDLINE on STN DUPLICATE 28
TI Cathepsin G-dependent platelet stimulation by activated polymorphonuclear leukocytes and its inhibition by antiproteases: role of **P-selectin**-mediated cell-cell adhesion.
SO Blood, (1993 Jun 1) 81 (11) 2947-57.
Journal code: 7603509. ISSN: 0006-4971.

AU Evangelista V; Piccardoni P; White J G; de Gaetano G; Cerletti C
AN 93271479 MEDLINE

L85 ANSWER 68 OF 120 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
TI KNOWLEDGE-BASED MODEL-BUILDING OF PROTEINS - CONCEPTS AND EXAMPLES
SO PROTEIN SCIENCE, (NOV 1993) Vol. 2, No. 11, pp. 1798-1810.
ISSN: 0961-8368.

AU BAJORATH J (Reprint); STENKAMP R; ARUFFO A
AN 93:665534 SCISEARCH

L85 ANSWER 69 OF 120 MEDLINE on STN DUPLICATE 29
TI Soluble **P-selectin** is present in normal circulation and its plasma level is elevated in patients with thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome.
SO British journal of haematology, (1993 Aug) 84 (4) 702-10.
Journal code: 0372544. ISSN: 0007-1048.

AU Katayama M; Handa M; Araki Y; Ambo H; Kawai Y; Watanabe K; Ikeda Y
AN 94031831 MEDLINE

L85 ANSWER 70 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Primary structures of platelet aggregation inhibitors (disintegrins) autoproteolytically released from snake **venom** hemorrhagic **metalloproteinases** and new fluorogenic peptide substrates for these enzymes
SO Journal of Biochemistry (Tokyo, Japan) (1993), 113(4), 473-83
CODEN: JOBIAO; ISSN: 0021-924X

AU Takeya, Hiroyuki; Nishida, Shinji; Nishino, Norikazu; Makinose, Yuichi;

Omori-Satoh, Tamotsu; Nikai, Toshiaki; Sugihara, Hisayoshi; Iwanaga, Sadaaki
 AN 1993:644147 HCAPLUS
 DN 119:244147

L85 ANSWER 71 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 TI Leukocyte interactions with **P-selectin**.
 SO Journal of Cellular Biochemistry Supplement, (1993) Vol. 0, No. 17 PART A, pp. 326.
 Meeting Info.: Keystone Symposium on Cell Adhesion Mechanisms in Leukocyte Traffic. Keystone, Colorado, USA. January 24-31, 1993.
 ISSN: 0733-1959.
 AU McEver, Rodger P. [Reprint author]; Warren, W. K.
 AN 1993:200532 BIOSIS

L85 ANSWER 72 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 TI Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors.
 SO Laboratory Investigation, (1993) Vol. 69, No. 3, pp. 312-321.
 CODEN: LAJNLA. ISSN: 0023-6837.
 AU Autio-Harmainen, Helena [Reprint author]; Karttunen, Tuomo; Hurskainen, Tiina; Hoyhtya, Matti; Kauppila, Antti; Tryggvason, Karl
 AN 1993:525343 BIOSIS

L85 ANSWER 73 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 TI Functional analysis of **P-selectin** MABs of the selectin panel.
 SO Tissue Antigens, (1993) Vol. 42, No. 4, pp. 263.
 Meeting Info.: 5th International Conference on Human Leukocyte Differentiation Antigens. Boston, Massachusetts, USA. November 3-7, 1993.
 CODEN: TSANA2. ISSN: 0001-2815.
 AU De Bruijne-Admiraal, Lucia G.; Von Dem Borne, Albert E. G. K.
 AN 1994:91308 BIOSIS

L85 ANSWER 74 OF 120 MEDLINE on STN DUPLICATE 30
 TI Platelet alpha-granules.
 SO Blood reviews, (1993 Mar) 7 (1) 52-62. Ref: 138
 Journal code: 8708558. ISSN: 0268-960X.
 AU Harrison P; Cramer E M
 AN 93222704 MEDLINE

L85 ANSWER 75 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 TI Synthetic peptides from the lectin domains of the selectins inhibit leukocyte adhesion in vitro and in vivo.
 SO Abstracts of Papers American Chemical Society, (1993) Vol. 206, No. 1-2, pp. MEDI 257.
 Meeting Info.: 206th ACS (American Chemical Society) National Meeting. Chicago, Illinois, USA. August 22-27, 1993.
 CODEN: ACSRAL. ISSN: 0065-7727.
 AU Heavner, George A.
 AN 1993:473032 BIOSIS

L85 ANSWER 76 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
 TI Characterization of C3o, a novel cleavage product of human complement component C3, and of the complement activation **protease** from **Naja naja venom** used to generate C3o
 SO (1992) 142 pp. Avail.: Univ. Microfilms Int., Order No. DA9236644
 From: Diss. Abstr. Int. B 1993, 53(7), 3392
 AU O'Keefe, Mary Clare
 AN 1994:104521 HCAPLUS
 DN 120:104521

L85 ANSWER 77 OF 120 MEDLINE on STN DUPLICATE 31
 TI **P-selectin** and E-selectin. Distinct but overlapping

leukocyte ligand specificities.

SO Journal of biological chemistry, (1992 Jun 5) 267 (16) 11104-10.
Journal code: 2985121R. ISSN: 0021-9258.

AU Larsen G R; Sako D; Ahern T J; Shaffer M; Erban J; Sajer S A; Gibson R M;
Wagner D D; Furie B C; Furie B

AN 92283809 MEDLINE

L85 ANSWER 78 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN

TI The edema-inducing activity of king **cobra** (*Ophiophagus hannah*)
venom proteases

SO Recent Adv. Toxinol. Res., [World Conf. Anim., Plant Microb. Toxin], 10th
(1992), Volume 1, 647-56. Editor(s): Gopalakrishnakone, P.; Tan, Choon
Kim. Publisher: Natl. Univ. Singapore, Venom Toxin Res. Group, Singapore,
Singapore.
CODEN: 58UAAH

AU Tan, Nget Hong; Yong, Wai Ying

AN 1993:162890 HCAPLUS

DN 118:162890

L85 ANSWER 79 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

TI THE OEDEMA-INDUCING ACTIVITY OF KING **COBRA** OPHIOPHAGUS-HANNAH
VENOM PROTEASES.

SO Toxicon, (1992) Vol. 30, No. 5-6, pp. 555.
Meeting Info.: TENTH WORLD CONGRESS ON ANIMAL, PLANT AND MICROBIAL TOXINS,
SINGAPORE, SINGAPORE, NOVEMBER 3-8, 1991. TOXICON.
CODEN: TOXIA6. ISSN: 0041-0101.

AU TAN N-H [Reprint author]; YOUNG W-Y

AN 1992:490536 BIOSIS

L85 ANSWER 80 OF 120 MEDLINE on STN DUPLICATE 32

TI Identification of a specific glycoprotein ligand for **P-selectin** (CD62) on myeloid cells.

SO Journal of cell biology, (1992 Jul) 118 (2) 445-56.
Journal code: 0375356. ISSN: 0021-9525.

AU Moore K L; Stults N L; Diaz S; Smith D F; Cummings R D; Varki A; McEver R
P

AN 92332600 MEDLINE

L85 ANSWER 81 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

TI Binding of calcium to the lectin domain of **P-selectin**
enhances its resistance to proteolytic degradation.

SO Circulation, (1992) Vol. 86, No. 4 SUPPL. 1, pp. I407.
Meeting Info.: 65th Scientific Sessions of the American Heart Association.
New Orleans, Louisiana, USA. November 16-19, 1992.
CODEN: CIRCAZ. ISSN: 0009-7322.

AU Geng, Jian-Guo; McEver, Roger P.

AN 1993:267114 BIOSIS

L85 ANSWER 82 OF 120 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN

TI STRUCTURAL DOMAINS IN **VENOM** PROTEINS - EVIDENCE THAT
METALLOPROTEINASES AND NONENZYMATIC PLATELET-AGGREGATION
INHIBITORS (DISINTEGRINS) FROM SNAKE-VENOMS ARE DERIVED BY PROTEOLYSIS
FROM A COMMON PRECURSOR

SO TOXICON, (MAR 1992) Vol. 30, No. 3, pp. 265-293.
ISSN: 0041-0101.

AU KINI R M (Reprint); EVANS H J

AN 92:291318 SCISEARCH

L85 ANSWER 83 OF 120 MEDLINE on STN DUPLICATE 33

TI **P-selectin** mediates Ca(2+)-dependent adhesion of
activated platelets to many different types of leukocytes: detection by
flow cytometry.

SO Blood, (1992 Jul 1) 80 (1) 134-42.
Journal code: 7603509. ISSN: 0006-4971.

AU de Bruijne-Admiraal L G; Modderman P W; Von dem Borne A E; Sonnenberg A
AN 92305322 MEDLINE

L85 ANSWER 84 OF 120 MEDLINE on STN DUPLICATE 34
TI A monoclonal antibody-based enzyme immunoassay for human GMP-140/**P**
-**selectin**.
SO Journal of immunological methods, (1992 Aug 30) 153 (1-2) 41-8.
Journal code: 1305440. ISSN: 0022-1759.

AU Katayama M; Handa M; Ambo H; Araki Y; Hirai S; Kato I; Kawai Y; Watanabe K; Ikeda Y
AN 92388723 MEDLINE

L85 ANSWER 85 OF 120 MEDLINE on STN
TI GMP-140 binds to a glycoprotein receptor on human neutrophils: evidence for a lectin-like interaction.
SO Journal of cell biology, (1991 Feb) 112 (3) 491-9.
Journal code: 0375356. ISSN: 0021-9525.

AU Moore K L; Varki A; McEver R P
AN 91123302 MEDLINE

L85 ANSWER 86 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Comparative enzymic composition of Brazilian coral snake (*Micrurus*) venoms
SO Comparative Biochemistry and Physiology, Part B: Biochemistry & Molecular Biology (1991), 99B(2), 287-94
CODEN: CBPBB8; ISSN: 0305-0491

AU Aird, Steven D.; Jorge da Silva, Nelson, Jr.
AN 1991:673026 HCAPLUS
DN 115:273026

L85 ANSWER 87 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI PURIFICATION AND CHARACTERIZATION OF TWO C3-CLEAVING **PROTEASES** FROM **COBRA VENOM**.
SO Complement and Inflammation, (1991) Vol. 8, No. 3-4, pp. 210.
Meeting Info.: XIVTH INTERNATIONAL COMPLEMENT WORKSHOP, CAMBRIDGE, ENGLAND, UK, SEPTEMBER 15-20, 1991. COMPLEMENT INFLAMMATION.
CODEN: CMPIE7. ISSN: 1012-8204.

AU PETRELLA E C [Reprint author]; O'KEEFE M C; BREDEHORST R; VOGEL C-W
AN 1991:518784 BIOSIS

L85 ANSWER 88 OF 120 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 35
TI Effect of king **cobra venom** on α 2-macroglobulin and **proteases** in human blood plasma.
SO Journal of Biosciences, (1990) 15/2 (59-66).
ISSN: 0250-5991 CODEN: JOBSDN

AU Roche M.; Pattabiraman T.N.
AN 91026181 EMBASE

L85 ANSWER 89 OF 120 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
TI EFFECT OF KING **COBRA VENOM** ON ALPHA-2-MACROGLOBULIN AND **PROTEASES** IN HUMAN BLOOD-PLASMA
SO JOURNAL OF BIOSCIENCES, (1990) Vol. 15, No. 2, pp. 59-66.

AU ROCHE M (Reprint); PATTABIRAMAN T N
AN 90:444107 SCISEARCH

L85 ANSWER 90 OF 120 MEDLINE on STN
TI Structural and biosynthetic studies of the granule membrane protein, GMP-140, from human platelets and endothelial cells.
SO Journal of biological chemistry, (1989 Jan 25) 264 (3) 1816-23.
Journal code: 2985121R. ISSN: 0021-9258.

AU Johnston G I; Kurosky A; McEver R P
AN 89109204 MEDLINE

L85 ANSWER 91 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

TI A C3-CLEAVING **PROTEASE** FROM **COBRA VENOM**
 INDUCES COMPLEMENT-DEPENDENT HEMOLYSIS.
 SO Complement and Inflammation, (1989) Vol. 6, No. 5, pp. 381.
 Meeting Info.: XIIITH INTERNATIONAL COMPLEMENT WORKSHOP, SAN DIEGO,
 CALIFORNIA, USA, SEPTEMBER 10-15, 1989. COMPLEMENT INFLAMMATION.
 CODEN: CMPIE7. ISSN: 1012-8204.
 AU O'KEEFE M C [Reprint author]; HAMMER C H; VOGEL C-W
 AN 1990:64587 BIOSIS

L85 ANSWER 92 OF 120 MEDLINE on STN
 TI Effects of **venom proteases** on peptide chromogenic
 substrates and bovine prothrombin.
 SO Toxicon : official journal of the International Society on Toxinology,
 (1989) 27 (2) 161-7.
 Journal code: 1307333. ISSN: 0041-0101.
 AU Teng C M; Wang J P; Huang T F; Liao M Y
 AN 89242686 MEDLINE

L85 ANSWER 93 OF 120 MEDLINE on STN DUPLICATE 36
 TI A novel cleavage product of human complement component C3 with structural
 and functional properties of **cobra** venom factor.
 SO Journal of biological chemistry, (1988 Sep 5) 263 (25) 12690-7.
 Journal code: 2985121R. ISSN: 0021-9258.
 AU O'Keefe M C; Caporale L H; Vogel C W
 AN 88315071 MEDLINE

L85 ANSWER 94 OF 120 MEDLINE on STN DUPLICATE 37
 TI A **protease** in the **venom** of king **cobra**
 (Ophiophagus hannah): purification, characterization and substrate
 specificity on oxidized insulin B-chain.
 SO Toxicon : official journal of the International Society on Toxinology,
 (1988) 26 (12) 1145-55.
 Journal code: 1307333. ISSN: 0041-0101.
 AU Yamakawa Y; Omori-Sato H
 AN 89187830 MEDLINE

L85 ANSWER 95 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 TI STRUCTURAL STUDIES OF FIBRINOGEN AFTER MODIFICATION WITH A SNAKE
VENOM PROTEASES.
 SO Journal of Cell Biology, (1988) Vol. 107, No. 6 PART 3, pp. 826A.
 Meeting Info.: JOINT MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY AND
 THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, SAN
 FRANCISCO, CALIFORNIA, USA, JANUARY 29-FEBRUARY 2, 1989. J CELL BIOL.
 CODEN: JCLBA3. ISSN: 0021-9525.
 AU ELLIOTT B W JR [Reprint author]; ORIEL B; EVANS H J; COHEN C
 AN 1989:193692 BIOSIS

L85 ANSWER 96 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 TI EFFECT OF ENVENOMATION ON DIFFERENT LIPID PROFILES OF LIVER MICROSOMAL
 FRACTIONS OF ALBINO RATS.
 SO Indian Journal of Experimental Biology, (1988) Vol. 26, No. 3, pp.
 241-242.
 CODEN: IJEB A6. ISSN: 0019-5189.
 AU BHATTACHARYYA A [Reprint author]; MAITY C R; MAJUMDAR G
 AN 1988:231663 BIOSIS

L85 ANSWER 97 OF 120 MEDLINE on STN DUPLICATE 38
 TI Effect of **cobra** and viper venoms on alpha 2-macroglobulin
 activity in human, bovine, and goat sera.
 SO Biochemical medicine and metabolic biology, (1988 Apr) 39 (2) 217-25.
 Journal code: 8605718. ISSN: 0885-4505.
 AU Sujatha S; Jacob R T; Pattabiraman T N
 AN 88240785 MEDLINE

L85 ANSWER 98 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI EFFECT OF ENVENOMATION ON HUMAN SERUM ALPHA-2 MACROGLOBULIN AND TOTAL
ANTITRYPTIC ACTIVITY.
SO Indian Journal of Medical Research, (1985) Vol. 82, No. DEC, pp. 551-553.
CODEN: IJMRAQ. ISSN: 0019-5340.
AU RAO N R [Reprint author]; PATTABIRAMAN T N
AN 1986:285631 BIOSIS

L85 ANSWER 99 OF 120 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN
TI Characterization of a **protease** from **cobra**
venom that cleaves the human complement component C3.
SO Federation Proceedings, (1984) 43/7 (no. 3132).
CODEN: FEPRA7
AU O'Keefe M.C.; Vogel C.-W.; Caporale L.H.
AN 84217816 EMBASE

L85 ANSWER 100 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Enzymic inactivation of human α 1-antichymotrypsin by
metalloproteinases in snake venoms of the family Elapidae
SO Comparative Biochemistry and Physiology, Part B: Biochemistry & Molecular
Biology (1984), 77B(3), 431-6
CODEN: CBPBB8; ISSN: 0305-0491
AU Kress, Lawrence F.; Hufnagel, Mary E.
AN 1984:186990 HCAPLUS
DN 100:186990

L85 ANSWER 101 OF 120 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN
TI C3o, a new cleavage product of human C3 generated by a **protease**
from **cobra venom**.
SO Federation Proceedings, (1984) 43/6 (no. 184).
CODEN: FEPRA7
AU Caporale L.H.; O'Keefe M.C.; Vogel C.-W.
AN 84197472 EMBASE

L85 ANSWER 102 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Protease inhibitor homologs from mamba venoms: facilitation of
acetylcholine release and interactions with prejunctional blocking toxins
SO British Journal of Pharmacology (1982), 77(1), 153-61
CODEN: BJPCBM; ISSN: 0007-1188
AU Harvey, A. L.; Karlsson, E.
AN 1983:48319 HCAPLUS
DN 98:48319

L85 ANSWER 103 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI SEPARATION OF PROTEIN AND ENZYME COMPONENTS OF VENOM OF THE INDIAN
COBRA NAJA-NAJA UNDER DIS AGGREGATING
CONDITIONS.
SO Proceedings of the Indian National Science Academy Part B Biological
Sciences, (1980) Vol. 46, No. 5, pp. 603-614.
CODEN: PIBSBB. ISSN: 0073-6600.
AU ACHYUTHAN K E [Reprint author]; RAMACHANDRAN L K
AN 1981:292609 BIOSIS

L85 ANSWER 104 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI IMMUNE COMPLEX VASCULITIS IN BEIGE MICE.
SO Federation Proceedings, (1979) Vol. 38, No. 3 PART 1, pp. 1003.
CODEN: FEPRA7. ISSN: 0014-9446.
AU JOHNSON K J; VARANI J
AN 1979:64114 BIOSIS

L85 ANSWER 105 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Snake venom proteinase inhibitors. III. Isolation of five polypeptide

inhibitors from the venoms of Hemachatus haemachatus (Ringhal's **cobra**) and **Naja nivea** (Cape **cobra**) and the complete amino acid sequences of two of them

SO Journal of Biochemistry (Tokyo, Japan) (1976), 79(3), 559-78
 CODEN: JOBIAO; ISSN: 0021-924X

AU Hokama, Yasuji; Iwanaga, Sadaaki; Tatsuki, Tsuru; Suzuki, Tomoji
 AN 1976:161072 HCAPLUS
 DN 84:161072

L85 ANSWER 106 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
 TI Relation between enzymic activities and pathohistological changes caused by fractionated Habu venom
 SO Taiwan Yixuehui Zazhi (1972), 71(6), 408-12
 CODEN: TIHHAH; ISSN: 0371-7682

AU Sato, Hachiro; Takaki, Shigeo
 AN 1973:12451 HCAPLUS
 DN 78:12451

L85 ANSWER 107 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
 TI Puff adder (Bitis arietans) **venom**. II. Specificity of **protease A**
 SO Toxicon (1972), 10(4), 341-9
 CODEN: TOXIA6; ISSN: 0041-0101

AU Van der Walt, S. J.; Joubert, F. J.
 AN 1972:471872 HCAPLUS
 DN 77:71872

L85 ANSWER 108 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
 TI Protease activity as a possible mechanism of migration inhibitory factor
 SO European Journal of Immunology (1972), 2(1), 97-9
 CODEN: EJIMAF; ISSN: 0014-2980

AU Havemann, Klaus; Horvat, M.; Sodomann, C. P.; Havemann, Karin; Buerger, Sigrid
 AN 1972:432446 HCAPLUS
 DN 77:32446

L85 ANSWER 109 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
 TI Phospholipase A and protease activities in Bothrops and Crotalus venoms. Effect on the mitochondrial respiratory chain
 SO Revista de la Sociedad Argentina de Biologia (1971), 47(5-8), 173-86
 CODEN: RSABAC; ISSN: 0037-8380

AU Badano, Blanca N.; Stoppani, A. O. M.
 AN 1973:513365 HCAPLUS
 DN 79:113365

L85 ANSWER 110 OF 120 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 TI TYROSINASE IN MEMBRANE SYSTEM OF MOUSE MELANOMA.
 SO Journal of Investigative Dermatology, (1970) Vol. 54, No. 1, pp. 97.
 CODEN: JIDEAE. ISSN: 0022-202X.

AU SEIJI M; ITAKURA H; MIYAZAKI K; IRMAJIRI T
 AN 1970:81979 BIOSIS

L85 ANSWER 111 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
 TI Biochemical investigations on Heloderma venom
 SO Memorias do Instituto Butantan (1966), 33(3), 907-11
 CODEN: MIBUAH; ISSN: 0073-9901

AU Mebs, Dietrich; Raudonat, Heinz W.
 AN 1969:66397 HCAPLUS
 DN 70:66397

L85 ANSWER 112 OF 120 MEDLINE on STN DUPLICATE 39
 TI PROPERTIES OF AXON MEMBRANE AS AFFECTED BY **COBRA VENOM**, DIGITONIN, AND **PROTEASES**.
 SO American journal of physiology, (1964 Dec) 207 1441-6.

Journal code: 0370511. ISSN: 0002-9513.

AU NARAHASHI T; TOBIAS J M
AN 65056455 MEDLINE

L85 ANSWER 113 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Paper chromatography of snake poisons
SO Naunyn-Schmiedeberg's Archiv fuer Pharmakologie und Experimentelle Pathologie (1956), 228, 219
CODEN: APEPA2; ISSN: 0365-5423
AU Raudonat, H. W.
AN 1956:45048 HCAPLUS
DN 50:45048
OREF 50:8764b-c

L85 ANSWER 114 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
TI **Proteases of cobra (Naja naja) venom**
SO Publ. Am. Assoc. Advance. Sci. (1956), No. 44, 179-80
AU Rao, Shanta S.; Rao, Savur S.
AN 1957:43723 HCAPLUS
DN 51:43723
OREF 51:8183c-d

L85 ANSWER 115 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Action in vivo of some substances on the proteolytic system in blood
SO Indian Medical Gazette (1942), 77, 409-12
CODEN: IMGAAAY; ISSN: 0019-5863
AU Iyenger, N. K.; Dutt, N. K.; Mukerji, B.
AN 1943:6997 HCAPLUS
DN 37:6997
OREF 37:1190e-g

L85 ANSWER 116 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Enzymes in snake venom. IV
SO J. Indian Chem. Soc. (1938), 15, 566-72
AU Ghosh, B. N.; Chowdhury, D. K.
AN 1939:17325 HCAPLUS
DN 33:17325
OREF 33:2548f-g

L85 ANSWER 117 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Studies on the **protease of cobra venom**
SO Indian Journal of Medical Research (1913-1988) (1938), 26, 487-92
CODEN: IJMRAQ; ISSN: 0019-5340
AU Iyengar, N. K.; Sehra, K. B.; Mukerji, B.
AN 1939:48160 HCAPLUS
DN 33:48160
OREF 33:6888c

L85 ANSWER 118 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Enzymes in snake venom. III. Effect of temperature and chemicals on their activity
SO J. Indian Chem. Soc. (1937), 14, 564-71
AU Kundu, M. L.; De, S. S.; Ghosh, B. N.
AN 1938:17922 HCAPLUS
DN 32:17922
OREF 32:2547h-i

L85 ANSWER 119 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Enzymes in snake venom. I. Action on hemoglobin and on protein solutions of different pH
SO J. Indian Chem. Soc. (1936), 13, 450-5
AU Ghosh, B. N.
AN 1936:62014 HCAPLUS

DN 30:62014
OREF 30:8249f-i

L85 ANSWER 120 OF 120 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Effect of snake venom on the action of trypsin and pancreatic juice
SO Science and Culture (1936), 2, 223-4
CODEN: SCINAL; ISSN: 0036-8156
AU Ghosh, B. N.; De, S. S.
AN 1937:31115 HCAPLUS
DN 31:31115
OREF 31:4394b-d

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

198.68

198.89

STN INTERNATIONAL LOGOFF AT 10:46:48 ON 16 JUN 2004